RG1122763  
 
            Page 1 of 53   
  
 
FRED HUTCHINSON CANCER CENTER  
Current version: version 4, 5/10/2024  
Previous version : 12/15 /2023  
 
Version 4 5/10/24  
Version 3  12/15 /2023  
Version 2  6/5/ 2023  
Version 1  1/4/2023    
 
 
Title of Protocol:  
ACT on Vapi[INVESTIGATOR_007]: Development of a Digital Therapeutic for Young Adult Vapi[INVESTIGATOR_277554].   
 
Investigators List:  
Jaimee Heffner, PhD  Associate Professor , FHCC  (206) [ADDRESS_338956] Manager , FHCC  (206) 667 -2428  
Medical Monitor:  
Panagis Galiatsatos, 
MD Assistant Professor, Johns Hopkins School of Medicine  ([PHONE_5735]  
Biostatistician:  
Kelsey Baker, M.S.  Cancer Center Biostatistical Shared Resource  (206) 667 -6655  
 
SPONSOR:  National Institute on Drug Abuse  
  
RG1122763  
 
            Page [ADDRESS_338957] on Vapi[INVESTIGATOR_007]: Digital Therapeutic for Young Adult Vapi[INVESTIGATOR_277555] [ADDRESS_338958] matter experts (YAs who vape, 
team members with expertise in YA vapi[INVESTIGATOR_007]) to develop vapi[INVESTIGATOR_007] -focused 
content for the novel program.  
b. Conduct a pi[INVESTIGATOR_4265] (n=60) to evaluate acceptability and preliminary 
efficacy of ACT on Vapi[INVESTIGATOR_277556] a n incentivized text message  control 
condition.  Trial go/no -go criteria for proceeding to a subsequent Phase II 
trial are: (1) satisfaction with ACT on Vapi[INVESTIGATOR_277557] 3.5 out of 5; 
and, (2) relative to control, evidence of better outcomes on at least 1 of 3 
efficacy endpoints: change in readiness to quit (mean difference in 
Contemplation Ladder change scores ≥ 1), 24 -hour quit attempts (≥  5% 
difference), and cotinine -confirmed 30 -day point prevalence abstinence 
from all nicotine/tobacco products at 3 months (≥ 5% difference).  
Study Design  2-arm randomized controlled pi[INVESTIGATOR_124250] 1:1 parallel assignment  
Population  Young a dult e -cigarette users  
Primary Endpoints  Treatment acceptability:  
• Satisfaction  with  the assigned  intervention  on a 5- point Likert -type 
scale at [ADDRESS_338959] -randomization  
Cessation  
• Change in Contemplation Ladder  scores  from  baseline: Change  in 
readiness  to quit using  e-cigarettes at 3-months post -randomization  
• Self-reported  24-hour  quit attempt: Proportion of participants 
making a quit attempt lasting at least [ADDRESS_338960] -randomization  
• Cotinine -confirmed 30 -day point prevalence abstinence from  all 
nicotine  and tobacco (excluding FDA -approved pharmacotherapi[INVESTIGATOR_014]) 
3-months post -randomization  
Secondary Endpoints   
Type of control   Incentivized text messages assessing vapi[INVESTIGATOR_277558]  2 arm; ACT on Vapi[INVESTIGATOR_277559]  3 months p articipants will be encouraged to use 
their online program as desired  during that time . 
Number of trial subjects  n=[ADDRESS_338961] Randomized Controlled Trial  
PPA Point Prevalence Abstinence  
USCPG  US Clinical Practice Guidelines  
YA Young Adult  
  
RG1122763  
 
            Page 4 of 53   
 Table of Contents  
1.0 GENERAL INFORMATION  ................................ ................................ ................................ ................................ ..................  7 
1.1 Protocol Title: ACT on Vapi[INVESTIGATOR_007]: Development of a Digital Therapeutic for Young Adult Vapi[INVESTIGATOR_277560]  .........  7 
1.2 Sponsor Information: National Institutes of Health, Grant Number: 1UG3DA057032  ................................ .......  7 
1.3 Investigator Information:  ................................ ................................ ................................ ................................ ..... 7 
1.4 Contractors and Consultants for the Study (if applicable):  ................................ ................................ ..................  7 
2.0 INTRODUCTION TO THE PROTOCOL  ................................ ................................ ................................ ................................ . 8 
2.1 Introduction  ................................ ................................ ................................ ................................ .........................  8 
2.2 Preclinical Data  ................................ ................................ ................................ ................................ ..................  10 
2.3 Clinical Data to Date  ................................ ................................ ................................ ................................ ..........  10 
2.4 Study Agent  ................................ ................................ ................................ ................................ ........................  12 
2.5 Risks/Benefits ................................ ................................ ................................ ................................ .....................  14 
3.0 PRE-TRIAL INTERVENTION CONTENT DEVELOPMENT AND [LOCATION_003]BILITY TESTING  ................................ ............................  14 
1.1 Objectives:  ................................ ................................ ................................ ................................ .........................  14 
3.2 Usability Testing  ................................ ................................ ................................ ................................ .................  15 
4.0 OVERVIEW OF CLINICAL TRIAL  ................................ ................................ ................................ ................................ ........  15 
4.1 Study Objectives  ................................ ................................ ................................ ................................ ................  16 
4.2 Study Population  ................................ ................................ ................................ ................................ ................  16 
4.3 Study Design  ................................ ................................ ................................ ................................ ......................  16 
4.4 Estimated Accrual:  ................................ ................................ ................................ ................................ .............  17 
4.5 Name [CONTACT_790]/Funding Source: National Institutes of Health ................................ ................................ ...... [ADDRESS_338962] EVALUATION ................................ ................................ ................................ ................................ .....................  21 
8.1 Data Collection Overview  ................................ ................................ ................................ ................................ .. 21 
8.2 Enrollment Procedures  ................................ ................................ ................................ ................................ ...... 21 
8.3 Assessments/On -Study Clinical Evaluations  ................................ ................................ ................................ ...... [ADDRESS_338963] DISCONTINUATION OF ACTIVE TREATMENT  ................................ ................................ ................................ .... 23 
10.0 CONCOMITANT MEDICATIONS  ................................ ................................ ................................ ................................ .......  23 
11.0 ADVERSE EVENTS  ................................ ................................ ................................ ................................ ............................  24 
11.1 Adverse Events  ................................ ................................ ................................ ................................ ...................  24 
11.2 Collection and reporting of AEs and SAEs  ................................ ................................ ................................ ..........  24 
RG1122763  
 
            Page 5 of 53   
 Monitoring. ................................ ................................ ................................ ................................ ................................ ..........  24 
Reporting.  24 
Definitions  ................................ ................................ ................................ ................................ ................................ ...........  24 
Management of SAEs or other study risks  ................................ ................................ ................................ ..........................  25 
Attribution  ................................ ................................ ................................ ................................ ................................ ...........  25 
12.0 DATA AND SAFETY MONITORING PLAN  ................................ ................................ ................................ ..........................  25 
13.0 DATA MANAGEMENT/CONFIDENTIALITY  ................................ ................................ ................................ .......................  25 
14.0 STATISTICAL CONSIDERATIONS  ................................ ................................ ................................ ................................ .......  26 
14.1 Study Design  ................................ ................................ ................................ ................................ ......................  26 
14.2 Primary/Secondary Endpoints/Hypotheses and Analytical Methods  ................................ ................................  26 
14.3 Sample Size and Power  ................................ ................................ ................................ ................................ ...... 26 
14.4 Randomization  ................................ ................................ ................................ ................................ ...................  26 
14.5 Missing Data  ................................ ................................ ................................ ................................ ......................  27 
14.6 Ethnic and Gender Distribution Chart  ................................ ................................ ................................ ................  27 
15.0 INVESTIGATOR OBLIGATIONS  ................................ ................................ ................................ ................................ .........  27 
16.0 REFERENCES  ................................ ................................ ................................ ................................ ................................ .... 31 
17.0 APPENDICES  ................................ ................................ ................................ ................................ ................................ .... 36 
Appendix A:  DSMP ................................ ................................ ................................ ................................ ................................ .. 36 
1 Summary of the protocol  ................................ ................................ ................................ ................................ ................  39 
1.1 Brief description of the protocol  ................................ ................................ ................................ ........................  39 
1.2 The primary aims are:  ................................ ................................ ................................ ................................ ........  39 
1.3 Primary outcome measures  ................................ ................................ ................................ ...............................  39 
1.4 Inclusion/exclusion criteria  ................................ ................................ ................................ ................................  [ADDRESS_338964] to ensure the validity and integrity of the data  ................................ ................................  43 
4.2 Procedures to guarantee the accuracy and completeness of the data  ................................ .............................  43 
4.3 Procedures during data transmission  ................................ ................................ ................................ ................  44 
4.4 Procedures during data analysis  ................................ ................................ ................................ ........................  44 
5 Regulatory issues  ................................ ................................ ................................ ................................ ............................  44 
RG1122763  
 
            Page 6 of 53   
 5.1 Reporting mechanisms of AEs/SAEs to the IRB and NIDA  ................................ ................................ .................  [ADDRESS_338965] on Vapi[INVESTIGATOR_277561]: Recruitment  ................................ ................................ ................................ ........  [ADDRESS_338966] on Vapi[INVESTIGATOR_277562]/no -go criteria for proceeding to a fully -powered RCT: (1)  satisfaction  with ACT on Vapi[INVESTIGATOR_277557] 
3.5 out of 5; and, (2) relative to control, evidence of better outcomes on at least 1 of 3 efficacy endpoints: 
change in readiness to quit (mean difference in Contemplation Ladder change scores ≥ 1), 24 -hour quit attempts 
(≥ 5% difference), and cotinine -confirmed 30 -day point p revalence abstinence from all nicotine/tobacco 
products at 3 months (≥ 5% difference).   
 
Rationale  
The prevalence of vapi[INVESTIGATOR_277563] (YAs) has increased substantially in recent years . 
Almost one in ten YAs report current e -cigarette use, putting them at risk of developi[INVESTIGATOR_277564] -term health effects of exposure to inhaled toxicants  [11]. Despi[INVESTIGATOR_277565], very few treatments targeting any type of tobacco use among YAs have been evaluated, 
particularly for YA e -cigarette users, who have unique treatment needs. Innovative approaches a re needed to 
engage YAs in treatment, as they are low users of traditional treatme nt. They do appear to benefit from newer, 
digital treatment modalities combined with theory -driven therapeutic approaches. Also needed are 
interventions capable of engaging YAs across the spectrum of readiness to quit, as a majority will not be 
motivated t o quit at any given time and would benefit from encouragement to consider quitting.   
 
We developed a digital Acceptance and Commitment Therapy (ACT) program designed for YA cigarette smokers 
aged [ADDRESS_338967]’s overarching focus on increasing psychological flexibility offers 
a new approach for YAs to motivat e and support cessation, and ACT may have better efficacy than standard care 
approaches for tobacco cessation. The program also employs another exciting innovation: an avatar guide to 
make the program more engaging and effective. The original program, call ed Flexiquit, showed promise in 
motivating smoking cessation in a pi[INVESTIGATOR_2269] (RCT) with YAs in Cyprus, with a 29% self -
reported posttreatment quit rate for Flexiquit vs. 11% for waitlist control. Our single -arm pi[INVESTIGATOR_277566]: 93% satisfaction and a 23% 
biochemically confirmed  quit rate at [ADDRESS_338968] o n Vapi[INVESTIGATOR_277567] e - cigarette 
users in a 2 -arm randomized controlled pi[INVESTIGATOR_4251] (n=60 total with 1:1 allocation to the two treatment arms). The 
primary aim is to develop the pi[INVESTIGATOR_4251] -ready version of the ACT on Vapi[INVESTIGATOR_277568] -related targets.  We will test the intervention using 
a 3-months treatment period, and, consistent with the evaluation  period in our previous cessation app pi[INVESTIGATOR_11480], our primary outcomes will be assessed at the 3 -months end -of-treatment mark.  
 
1.1 Protocol Title : ACT on Vapi[INVESTIGATOR_007]:  Development of a  Digital Therapeutic for Young Adult Vapi[INVESTIGATOR_277560]  
 
1.2 Sponsor Information : National Institutes of Health, Grant Number:  1UG3DA057032  
1.3 Investigator Information :  
            Jaimee Heffner, Ph.D. (206) 667 -7314  
 
1.4 Contractors and Consultants for the Study (if applicable) : 
Megan Kelly, Ph.D. (The University of [LOCATION_005] and Edith Nourse Rogers Memorial Veterans 
Hospi[INVESTIGATOR_307] ) 
RG1122763  
 
            Page 8 of 53   
 Maria Karekla, Ph.D. (University of Cyprus, UCY)  
Amanda Graham, Ph.D. (Truth Initiat ive)  
Carla Berg, Ph.D., (George Washington University)  
Noreen Watson, Ph.D.  
Nandini Murthy, M.S., RAC ( ENEM Consulting ) 
Datatope LLC  
Moby [CONTACT_259555].  
 
 
2.0 INTRODUCTION TO THE PROTOCOL  
 
2.1 Introduction  
E-cigarette use has increased exponentially among YAs over time [1]. National Health Interview Survey (NHIS) 
data from 2019 show that 9.3% of YAs aged [ADDRESS_338969] in this a ge range [2].  
2.1.1 Problem and prevalence:  
E-cigarettes pose numerous risks, particularly to youth and YAs. Use of nicotine - containing e -cigarettes can lead 
to nicotine addiction, especially given that contemporary e -cigarette devices like Juul and pod -based e -
cigarettes that employ nicotine salt f ormulations expose users to high levels of nicotine and are more likely to 
lead to dependence [3].  Indeed, a majority (55 -69%) of YA e -cigarette users perceive themselves to be at least 
somewhat addicted [4]. In addition, longitudinal studies have demons trated increased risk of initiating and 
escalating cigarette smoking among adolescents and YAs who use e -cigarettes [5, 6]. Long -term health risks of e -
cigarettes require more study, but it is well -documented that e -cigarette aerosols contain toxicants int roduced 
by [CONTACT_277669] e -liquids as well as metals in the heating element [7]. These 
exposures are associated with number of health risks, including lung injury and inflammation, greater risk of 
respi[INVESTIGATOR_3765] (ast hma, COPD), and increased vulnerability to infection [7]. The 2016 US Surgeon General’s 
Report on e -cigarette use among adolescents and YAs highlighted these and other risks as part of a call to action 
to address the growing health threat posed by [CONTACT_158982][INVESTIGATOR_007] a mong young people [8].  
 
Young adulthood is a critical time for cessation interventions, as tobacco use behaviors can become entrenched 
during this period, and almost all tobacco -related harms can be prevented by [CONTACT_277670] 30 [9]. 
Unfortunately, very few treatment progra ms targeting any type of tobacco or nicotine product use among YAs 
have been developed and evaluated, particularly for YAs who are not in college. Thus, the literature on YA 
tobacco cessation treatment is sparse, has major methodological weaknesses, and ve ry few studies report long -
term follow -up data [10]. In a systematic review of YA cessation interventions, [ADDRESS_338970] -treatment and two improved cessation outcomes at 4 -6 month 
follow -up [10]. Given the recency with which e -cigarettes were introduced into the market and quickly become 
the most frequently used product among YAs, the current body of research on YA vapi[INVESTIGATOR_277569].  
2.1.[ADDRESS_338971] 
tobacco cessation programs. In a recent  review of the cessation treatment needs of YAs who vape [11], Drs. Berg 
(consultant), Graham (co -I), and co -authors outlined four focal areas for vapi[INVESTIGATOR_277570]. First, there is variability among YA e - cigarette users on type s of products used, resulting in differing levels 
of nicotine exposure and not identifying with common ways of describing their use (e.g., the term “smoker” or 
the concept of being addicted do not resonate for some). Second, although most YAs who vape use e-cigarettes 
exclusively and have no history of cigarette smoking [2], a substantial minority concurrently use other 
nicotine/tobacco products as well as cannabis and alcohol, which may make cessation more difficult. Third, YA e -
cigarette users have less e xtensive quit histories and low current readiness to quit. Only a small minority (6 -13%) 
RG1122763  
 
            Page 9 of 53   
 of YAs report that they’ve ever tried to quit vapi[INVESTIGATOR_277571] [4]. Similarly, findings from the Population 
Assessment of Tobacco and Health (PATH) study suggest that, although 62.3% of e -cigarette users reported 
planning to quit vapi[INVESTIGATOR_277572], onl y 15.7% reported plans to quit in the next month [12]. Fourth, YAs 
have unique reasons for continuing to vape, such as perceiving it to be less harmful than smoking or liking the 
flavors. They also have unique reasons for quitting vapi[INVESTIGATOR_007], such as dissatisf action with the taste or its perceived 
impact on cigarette smoking cessation. In addition to these points, there are also knowledge deficits, with YAs 
lacking awareness of the high nicotine content of pod devices like Juul [13]. Taken together, these findi ngs 
suggest that interventions are needed that target e -cigarette users across a broad spectrum of readiness to quit, 
with content that resonates for a population that is treatment -naïve and that may not identify with terms like 
“smoker” and addiction.” Ad ditionally, such programs must recognize and address motives for using or quitting 
e-cigarettes that differ from other tobacco product use. Standard treatment programs do not fit this description, 
and new programs are needed that are specific to young e -cigarette users.  
 
In addition to the need for vapi[INVESTIGATOR_007] -focused content, innovative approaches are needed to engage YAs in 
treatment, as they are low users of traditional treatment [14]. They do appear to prefer, and to benefit from, 
newer methods of treatment delivery (i.e., digital modalities), combined with theory -driven therapeutic 
approaches [10]. Digital therapeutics are advantageous for a number of reasons: (1) They have high potential 
reach relative to other treatment modalities; (2) COVID -19 has increased demand for re motely -delivered 
treatments, including digital health, for  a variety of purposes [15]; (3) YAs are digital natives who use technology 
and the internet in high numbers: 96% of YAs age 18 -29 are smartphone users [16] and 98% of YAs age 18 -29 
use the Internet [17]. Regarding preferences for digital tobacco treatment,  research conducted by [INVESTIGATOR_124]. Berg and 
colleagues [18] suggested that YA tobacco users (over 70% of whom used e -cigarettes) are highly interested in 
technology -delivered treatment, with the greatest p reference for smartphone apps (85.9%), followed by [CONTACT_277671] (62.1%), web -based programs (57.1%), social media –based programs (48.4%), and video 
counseling (41.6%). Data from Truth Initiative’s This is Quitting SMS text message program confirm tha t high 
numbers of YAs will use digital interventions for e -cigarette cessation when they are well -promoted [19]. Since 
This is Quitting launched in January 2019, more than 386,[ADDRESS_338972] enrolled (145,000 teens, 
241,000 YAs).  
 
Truth Initiative’s This is Quitting SMS text messaging program was the first and only digital intervention to be 
evaluated in a randomized controlled trial for YA vapi[INVESTIGATOR_82608]. In that trial [19], [ADDRESS_338973] -randomization under 
intent -to-treat analysis. Graham et al. found that 24.1% of the participants who received This is Quitting stopped 
vapi[INVESTIGATOR_277573] 18.6% in the ass essment -only arm (OR=1.39, 95% CI=1.15 -1.68, p <.001) providing support 
for the effectiveness of a digital treatment approach using text messaging. The effects of the program among 
YAs not currently preparing to quit vapi[INVESTIGATOR_277574], however, as th e sample was restricted to those who 
were ready to quit in the next 30 days.  
 
Acceptance and Commitment Therapy ( ACT) may be a more effective new treatment approach for tobacco use, 
with a novel mechanism of action: psychological flexibility. ACT [20, 21] is similar to standard US Public Health 
Service guidelines -based [22] cessation treatment in that it promotes awarene ss of the cues that trigger tobacco 
use, but different in that ACT teaches skills to increase psychological flexibility in response to triggers. 
Psychological flexibility is defined as willingness to experience the fu ll range of emotional, physical, and cognitive 
experiences without trying to change them (i.e., acceptance), and to do things that are difficult in service of 
one’s values (i.e., commitment) [23, 24]. Empi[INVESTIGATOR_277575] [ADDRESS_338974] relative to 
pharmacotherapy -only treatments and traditional behavioral treatments. In 8 of 10 studies [25 -34], quit rates 
for ACT were superior  to control group quit rates at both short - (i.e., 3 months) and long -term (6 to 12 months) 
follow -up. Together, these findings suggest that ACT is at least as effective, if not more so, than standard 
treatment. Regarding mechanisms of action, the research  to date has focused almost exclusively on one 
RG1122763  
 
            Page 10 of 53   
 component of psychological flexibility: acceptance, which mediated 60 -80% of treatment effects in previous 
studies of ACT for cessation among smokers ready to quit [25, 29]. Other dimensions of psychological flexibility 
require evaluation as mediators of t reatment effects, including changes in values -driven action.  
 
Previous trials of ACT for smoking cessation restricted enrollment to smokers who were ready to quit, and the 
intervention focused on action - oriented strategies for copi[INVESTIGATOR_277576]. However, ACT can also be 
employed to motivate tobacco users at lower  levels of quit readiness by [CONTACT_277672]. This approach is 
consistent with evidence -based approaches like motivational interviewing for tobacco users who are not 
currently ready to quit [ 74]. Our collaborator, [CONTACT_277707], developed the first ACT program designed for tobacco 
cessation among smokers at all stages of readiness to quit. This web - based program, Flexiquit, is also innovative 
in its use of gamification and avatar guides designed to represent the target user group(s) in order to motivate 
user interaction. These strategies are designed to increase engagement, and ultimately cessation outcomes, 
among smokers at all levels of quit readiness  by [CONTACT_277673], instilling hope through personal quitting narratives shared by [CONTACT_277674] a supportive peer who was able to quit successfully, and triggering the desired b ehavior with reminders and 
motivational “sparks” delivered both in -program and via messages (from Fogg’s Behavior Model for Persuasive 
Design [35]). To realize the benefits of an ACT -based digital therapeutic for YA e -cigarette users, we propose to 
develop  and evaluate the ACT on Vapi[INVESTIGATOR_277577], avatar -led treatment platform as its 
foundation.  
2.1.3 Summary of significance.  
This study  is significant in that:  (1) it focuses on a growing population of YAs who vape, (2) e -cigarette users are 
at risk for developi[INVESTIGATOR_277578]; (3) 
standard care tobacco interventions don’t address the unique treatment n eeds of YAs who vape, (4) YAs would 
benefit from a targeted program designed to address their treatment needs and preferences --specifically their 
preference for a smartphone app, tailored to their needs and challenges in a readily scalable and accessible 
format, and (5) there is high consumer demand for vapi[INVESTIGATOR_277579], as evidenced by 
241,000 YA enrollments to Truth Initiative’s This is Quitting  text messaging program between January [ADDRESS_338975] builds off of extensive preliminary work by [CONTACT_277675], as described below.  
 
Flexiquit:  Engaging, web -based, self -guided ACT for YA tobacco users at all levels of quit readiness.  Our 
collaborator, [CONTACT_277707], developed the first ACT program designed for YAs at all stages of readiness to quit. This 
web -based program, Flexiquit, is also innovative in its use of interactive games and avatar guides designed to 
represent the target us er group(s) in order to motivate user interaction. This program was evaluated among 84 
university student smokers in Cyprus, aged 18 -28 years (M age=22.4, SD=2.6) [37]. Participants were randomly 
assigned to either Flexiquit (n=49) or a wait -list control (n=35) group. Results indicated that program content 
was highly acceptable, even among those who had no intention to quit. Overall, 89% said the content was  easy 
to understand, 74% found it very interesting, and 57% completed all 6 sessions (which was incentivized in this 
proof -of-concept trial). Qualitative comments suggested that participants were surprised by [CONTACT_277676], even when they had started the 
program out of curiosity and had no intention to quit. The most commonly suggested changes to the program 
were technical and a direct result of the limited development budget for the initia l pi[INVESTIGATOR_20732]: e.g., improved 
RG1122763  
 
            Page 11 of 53   
 graphics for the avatar guide, technical improvements to enhance usability across web browsers. The program 
showed great promise in motivating cessation, with a 29% self -reported post -treatment quit rate for Flexiquit vs. 
11% for waitlist control (OR=3.10,  95% CI=0.92 -10.41). There were also statistically significant increases between 
baseline and end of treatment in self -efficacy and intention to quit as well as decreases in cigarettes per day and 
nicotine dependence. Treatment effects were maintained thro ugh 6 -month follow -up. Importantly, the majority 
(65%) of participants were in the precontemplation or contemplation stages of change, demonstrating the 
program’s utility for smokers who are at lower levels of quit readiness.  
 
Development and pi[INVESTIGATOR_277580] . In July 2018, we were awarded a 1 -year pi[INVESTIGATOR_277581] ( SGM ) YA cigarette smokers ages 18 -30 (PI: [INVESTIGATOR_259519]). The study team 
conducted user - centered design work to target the appearance and content of the intervention to address the 
needs and preferences of a US YA population identifying as SGM. Initial work include d: (1) developi[INVESTIGATOR_277582] -
targeted content to address known challenges to quitting in this group (e.g, minority stress, mental health  
conditions);  (2) c onducting two rounds of user interviews and a week -long diary study to test both cultural (i.e., 
Cyprus to US YA culture) and SGM adaptations to ACT exercises and related intervention content and to 
evaluate preferences for the avatar guide (e.g., level of  realism, appearance, backstory, voice), (3) redesigning 
the program structure for use on mobile devices, (4) adding closed captioning to make the content accessible, 
and (5) replacing post -session homework with SMS text messaging to remind participants of  key content 
covered.  We then conducted a single -arm pi[INVESTIGATOR_277583] (primary) and 
preliminary efficacy (secondary) for smoking cessation [38]. In 1 month we enrolled 22 YAs aged 18 -30 who 
identified as sexual minority (n=22) and/or gender mi nority (n=7). Of these 22 participants, 12 (55%) reported 
vapi[INVESTIGATOR_277584]. Over one -quarter (27%) identified as racial/ethnic minority. Baseline readiness to quit 
smoking ranged from 0 to 10 on the Contemplation Ladder, with  a mean of 6.2 (SD=2.7).  
 
Acceptability.  Among survey respondents, 93% rated EQQUAL as useful, 93% reported being satisfied with the 
program, and 87% said they would recommend it to a friend. Considering specific program components, 71% 
felt that text messages were useful and 93% reported that P DF handouts (e.g, benefits of quitting, smoking and 
the LGBTQ+ community) were useful. With regard to perceived targeting/tailoring, 93% said they felt like the 
program was made for them. All participants (100%) said the program was easy to n avigate, 100% reported that 
they felt more clear about how they might quit as a result of using the program, and 93% said it gave them new 
ways of looking at quitting. On the acceptability outcome of program usage, among those with at least one log -
in (n=1 8), mean number of log -ins was 5.5 (SD=3.6), average number of sessions completed was 3.1 (SD=2.6), 
and 39% (7/18) completed all 6 sessions.  
 
Smoking abstinence and motivation to quit. Biochemically -confirmed 7 -day PPA at 2 months was 22.7% (5/22) 
using the missing=smoking imputation and 31.3% (5/16) using the complete -case method. This represents [ADDRESS_338976] their cigarette abstinence verified via saliva cotinine. Self -reported, 7 -day PPA 
was 31.8% (7/22) in missing=smoking and 41% (7/17) in complete -case analysis. Results compare favorably to 
several histo rical control interventions for SGM YAs (see Table 1). Compared to the only other targeted digital 
intervention for SGM YAs —a professionally moderated Facebook intervention — the self -guided EQQUAL 
program’s biochemically -confirmed quit rate was over three times higher (23% vs.  7.1%). On the secondary 
outcome of self -reported 7 -day PPA, EQQUAL’s 31.8% quit rate also exceeds that of the SGM -targeted Facebook 
intervention (23.8%), a non -targeted Facebook intervention (12.3%), a non - targeted ACT intervention ( 18%), 
and Smokefree.gov (3.3% -8%). In addition to these promising quit rates, EQQUAL participants also showed an 
overall increase in motivation to quit, averaging a 2.1 -point increase (SD=3.0) on the 10 -point Contemplation 
Ladder. Of the 12 EQQUAL particip ants who used either e -cigarettes (n=11) or other non -cigarette products 
(n=1) at least weekly in addition to smoking cigarettes, 3 (25%) had cotinine -confirmed, 7 -day PPA from all 
nicotine -containing products. This suggests that this treatment approach ca n be effective at promoting 
abstinence from multiple forms of nicotine and tobacco use.  
 
RG1122763  
 
            Page 12 of 53   
  
 
Table  1. Studies  of digital  cessation  interventions  with  quit rates  available  for SGM  YAs 
Study/Intervention  
name  [CONTACT_277706],  # assigned  Quit  rate,  
verified**  Quit  rate,  self- 
report***  
EQQUAL  pi[INVESTIGATOR_2268]  [38] Targeted,  self-guided  ACT (n=22)  22.7%  31.8%  
Put It Out Project [39] Targeted,  moderated  social  media  
(n=84)  7.1%  23.8%  
Put It Out Project [39] Non -targeted,  moderated  social  media  
(n=75)  3.7%  12.3%  
Put It Out Project [39] Non -targeted,  self-guided  standard  care 
(Smokefree.gov) (n=60)  1.7%  3.3%  
WebQuit  [28, 40]*  Non -targeted,  self-guided  ACT (n=45)  N/A 18% 
WebQuit  [28, 40]*  Non -targeted,  self-guided  standard  care 
(Smokefree.gov) (n=48)  N/A 8% 
* Unpublished  subgroup  analysis;  ** Biochemically  confirmed  quit rate at  end of treatment,  missing=smoking;  *** 
Self-reported quit rate at end of treatment, missing=smoking  
 
Psychological flexibility. Exploration of changes in psychological flexibility showed descriptive increases in 
values -based action on the Valuing Questionnaire (VQ) [41]) and acceptance on the Avoidance and Inflexibility 
Scale (AIS) [30], all in the hypothesized direction.  
 
Perceptions of the avatar. Because of the novelty of the use of avatars within a cessation treatment program 
and the lack of guidance on how to effectively design avatars for this purpose, we included numerous 
quantitative and qualitative assessments of participant reactions to the avatar, “Jen.” On qualitative responses, 
Jen was described as human -like, supportive, and non -judgmental. For example: “She encouraged me when I 
thought I couldn’t quit smoking,” “She made it feel like a real person was there,” “ [I liked] her approachable, 
non-judgmental tone.” One participant even reported of Jen, “I’m in love with her.” When asked what they 
would change about Jen, two dominant themes emerged: (1) making the body movements more natural (e.g.,  
 “She just kinda moved a little awkwardly”) and (2) the need for the participant to be able to see themselves in 
the avatar’s appearance (e.g., “She should be a person of color so I can relate to her more.”). On the Agent 
Persona Inventory [42], all subsca le scores suggested very positive overall impressions of the avatar.  
 
Design and evaluation of other digital cessation interventions.  [CONTACT_273699] and colleagues developed the first 
web - and mobile -delivered ACT interventions for smoking cessation and evaluated them in randomized 
controlled trials. Specifically, aside from EQQUAL, the PI [INVESTIGATOR_277585] (SmartQuit 1.0, SmartQuit 2.0, iCanQuit, Actify, Quit2Heal, GEMS) [27, 32, 33, 43, 44] and two 
websites (WebQuit, WebQuit Plus) [28, 45] for smoking cessation. Of these [ADDRESS_338977] -based and 7 
are designed for those motivated to quit.  
 
2.4 Study Agent  
 
Control condition:  Incentivized text message check -ins. The control condition will be incentivized text message 
check -ins, similar to the design of Graham et al.’s [19] seminal study of a text messaging program (i.e., This is 
Quitting ) for vapi[INVESTIGATOR_82608]. Text message check -ins will occur at [ADDRESS_338978] -
randomization. At 2 weeks, participants will receive the following message: “Checking in: Have you cut down 
how much you vape nicotine in the past 2 weeks? Res pond w/ letter: A=I still use the same amount, B=I use less, 
C=I don’t use at  all anymore. Make sure to respond in the next 24 hrs to get your $5 incentive!” At 1 and 2 
months, they will receive the following message: “How’s it going? When was the last time you vaped nicotine, 
even a puff of someone else’s? Respond w/ letter: A - in the past 7 days, B - 8-30 days ago, C - More than 30 days 
ago. Make sure to respond in the next 24 hrs to get your $5 incentive!” Participants will be compensated $5 for 
each message that they respond to, for a maximum of $15 for responding to all 3 message s. In the Graham et al. 
[19] study, these text message check -ins were perceived as engaging and had placebo -like effects —e.g., 
RG1122763  
 
            Page 13 of 53   
 participants assigned to the control condition, on average, expressed agreement with the following statements 
about these messages: “They helped me feel more confident about quitting,” “I liked being able to interact with 
the text messages,” and “They made  me feel less alone in quitting.”  Because their perceived value in support of 
quitting, use of the incentivized text messages as a control condition allows for an estimate of the efficacy of the 
experimental ACT on Vapi[INVESTIGATOR_277586]. They are also designed to minimize attrition among participants assigned to the 
control arm. All participants assigned to the control condition will be given access to the ACT on Vapi[INVESTIGATOR_277587].   Participant responses to text message check -ins will 
not be analyzed as a study outcome.  
 
ACT on Vapi[INVESTIGATOR_007] . Consistent with the foundational Flexiquit/EQQUAL program, ACT on Vapi[INVESTIGATOR_277588] [ADDRESS_338979] -based [23, 24]. Later 
sessions include prompts to reduce vapi[INVESTIGATOR_277589] a quit date for stoppi[INVESTIGATOR_17528] (non -therapeutic) nicotine and 
tobacco use. Text messages  will be used to (a) prompt completion of the next session, and (b) push select 
intervention content to users. Messages  will be tailored to the user’s level of quit readiness, with those who are 
not ready to quit in the next 30 days receiving values -focused, motivational messages and those who are ready 
to quit in the next 30 days receiving action -oriented messages (e.g., identifying and responding to triggers). 
Content of the six ACT on Vapi[INVESTIGATOR_277590]:  
 
Session [ADDRESS_338980] concept of creative hopelessness —
recognizing that efforts to control thoughts, feelings, or sensations related  to vapi[INVESTIGATOR_007] (e.g., urges to vape) can be 
counterproductive. Session 3 completes the topic of creative hopelessness and introduces cognitive defusion —
i.e., psychological distancing from thoughts —as an alternative to thought control as a strategy for copi[INVESTIGATOR_007] w ith 
triggers. Session 4 completes the topic of cognitive defusion, encourages setting a quit date in the next week, 
and prompts users to practice defusing from thoughts that they won’t be able to quit as part of quit planning. 
Session 5 starts with a refle ction on recent successes and difficulties, introduces the acceptance strategy of 
willingness as a means of handling triggers, and covers relapse prevention via self -compassion and re -
commitment to quitting. Session 6 also starts with a reflection on recen t successes and difficulties, reviews 
content from previous sessions, and ends with a video emphasizing the importance letting go of the need to 
control feelings, sensations, and thoughts in order to follow one’s valued life direction.  
 
New vapi[INVESTIGATOR_007] -targeted treatment content will include short, animated  videos embedded into the ACT - focused 
content that provide brief advice to quit and education about the risks of vapi[INVESTIGATOR_007], benefits of quitting, and 
evidence -based guidance on how to quit that follows US Clinical Practice Guidelines for tobacco dependence 
treatment (e.g., information about cessation medications, setting a quit date, seeking support, etc.) [22]. In 
addition to this content, other areas in which the program will be targeted to a ddress vapi[INVESTIGATOR_277591] 
(1) the persona and narrative of the avatar guide, which will be presented as a former e -cigarette user who has 
successfully quit, (2) the narratives of other program users who share quit stories, (3) examples provided for 
implementing ACT strategies to reduce or quit vapi[INVESTIGATOR_007], and (4) the intervention content of the text messages  that 
accompany the program. To address the issue of co -occurring alcohol and marijuana use and other tobacco use 
as impediments to quitting, ACT on V api[INVESTIGATOR_277592] (e.g., explaining how the ACT strategy of acceptance could also be applied to situations that trigger 
alcohol use or cigarette smoking) and personal narrative format ( e.g., sharing stories of other YAs who quit 
vapi[INVESTIGATOR_277593], connecting personal values to decisions about substance use more 
broadly).  
 
RG1122763  
 
            Page [ADDRESS_338981] on Vapi[INVESTIGATOR_277594], at the same time intervals: [ADDRESS_338982] 
on engagement across arms, preventing differential attrition.  
 
Study agent  assignment :  Following the completion of the baseline and contact [CONTACT_277677] a  text message with a link. Once this link is clicked an automated algorithm will 
randomize participant s 1:[ADDRESS_338983] on Vapi[INVESTIGATOR_204494], with  login credentials  to access the app . 
If in 3 days the participant has not opened the app, they will receive a text message reminder.  If in 3 more days 
the participant has still not opened the app, study staff will reach out by [CONTACT_277678].  
 
2.5 Risks/Benefits  
 
Potential Risks : Participants will be told that the study may involve the following risks and/or discomforts:  
 
Therapeutic risks.  Therapeutic risks include the physical and psychological consequences of nicotine and 
tobacco abstinence, such as nicotine withdrawal symptoms. Participants will be informed of the 
discomfort associated with nicotine withdrawal, including common withdrawa l symptoms. Participants 
will also be informed of the possibility that  the intervention provided as part of the study may not be 
effective in helpi[INVESTIGATOR_277595].  
 
Research risks.  Participants will be informed of the following research -related risks: (1) the possibility 
that answering some questions may be emotionally upsetting, and (2) the possibility of breach of 
confidentiality. It is possible that some of the questions asked of  participants may cause some emotional 
discomfort. There is also a small risk of breach of confidentiality if participant data were to be accessed 
by [CONTACT_259550].  
 
Potential Benefits of the Proposed Research to the Subjects and Others  
Participants will be provided with information regarding potential benefits of participation in the study, 
including:  
1) the possibility that the study intervention might help them to quit using nicotine and tobacco, and  
2) access to a smartphone app to learn about their interest in quitting vapi[INVESTIGATOR_277596].  
 
Importance of the Knowledge to be Gained  
This study involves development and testing of an intervention that, if found to be effective, could have an 
enduring, positive impact on the high prevalence of e -cigarette use among young adults. As such, the minimal 
risks associated with participation in  the proposed study are exceeded by [CONTACT_277679].  
 
 
3.0 PRE-TRIAL INTERVENTION  CONTENT DEVELOPMENT AND  [LOCATION_003]BILITY TESTING  
 
1.1 Objectives:  
Add vapi[INVESTIGATOR_277597] 
(n~6-12), and conduct a heuristic evaluation, conducted by [CONTACT_277680], to evaluate usability   
 
3.1.[ADDRESS_338984] on Vapi[INVESTIGATOR_277598], we will recruit ~6-12 young adults , ages 18 -30, who meet 
basic eligibility criteria for the trials described below.  
RG1122763  
 
            Page 15 of 53   
  
Participants will be recruited nationally via one or more recruitment strategies used successfully in our previous 
studies (e.g, social media, targeted Craigslist ads).  
3.1.[ADDRESS_338985]. Heffner’s team . To create vapi[INVESTIGATOR_277599], we will: 1) conduct one on one interviews  with young 
adults, including e -cigarette users (n ~6-12), 2) utilize the existing literature on barriers to, and facilitators of, 
vapi[INVESTIGATOR_277600], and 3) utilize the clinical and research expertise of the investigative 
team in smoking cessation, ACT, and treating young adult s and vulnerable populations of e-cigarette users . 
Expected outcomes of this formative research include common barriers to quitting experienced by [CONTACT_91948], in 
their own words; composite narratives of their experiences with overcoming the challenges of quitting (“Quit 
Stories”) —an effective health communica tion tool (12) which can be relayed by [CONTACT_277681]; and 
desirable characteristics of virtual coaches. Content updates and design  changes to the app will be made on the 
basis of this formative work.  
 
1:1 Interviews will proceed in 1 -2 rounds of ~6 participants each, with recruitment continuing until thematic 
saturation is achieved within each round (i.e., no new themes emerge from interviews). If major changes are 
required after the first round of interview s, another group of ~6 participants will be recruited to provide 
feedback on the new designs, with recruitment continuing until thematic saturation is achieved.  The total 
estimated sample size needed for 1:1 interviews is therefore ~[ADDRESS_338986] a heuristic  evaluation of its 
usability  using expert reviewers . Usability is the extent to which a digital intervention can be easily navigated 
and understood by [CONTACT_28024] [52]. Usability is a critical outcome of the intervention development process, as low 
usability can undermine engagement with the intervention as w ell as its potential efficacy for tobacco cessation 
[53].  
3.1.3 Primary Objective:  
Completed development of the ACT o n Vapi[INVESTIGATOR_277601]. The 
ACT on Vapi[INVESTIGATOR_277602].  
3.2 Usability Testing  
A Heuristic evaluation with students (n=10) of the Human Centered Design Center at the University of 
Washington will be conducting by a UX Researcher to uncover any usability issues . A heuristic evaluation is an 
effective and fast method for uncovering any usability issues.   
 
3.[ADDRESS_338987] on Vapi[INVESTIGATOR_277603]’ s content 
and structure as well as to address any technical difficulties experienced. Based on prior work, the types of 
changes needed at this stage of development are typi[INVESTIGATOR_277604] (e.g., font size, color), changes to the wording of specific messages, or de -
bugging new features (e.g., inactive buttons). The Moby [CONTACT_259555]. programming team will then make changes needed 
to improve t he usability and/or content of the app. The final version of ACT on Vapi[INVESTIGATOR_277603], that will be 
developed after the heuristic evaluation , and will be used in the pi[INVESTIGATOR_4265].  
 
4.[ADDRESS_338988] on Vapi[INVESTIGATOR_277605] e -cigarette users 
in a 2 -arm randomized controlled pi[INVESTIGATOR_4251] (n=60 total with 1:1 allocation to the two arms). The primary aim 
is to develop  the pi[INVESTIGATOR_4251] -ready version of the ACT on Vapi[INVESTIGATOR_277606] -related targets.  
 
4.1.1 Primary Endpoints  
o Treatment acceptability as indicated by o verall  treatment  satisfaction rating  
o Treatment efficacy:   
▪ Change in Contemplation Ladder  scores  from  baseline to [ADDRESS_338989] -randomization  
▪ Self-reported  24-hour  quit attempt at 3-months post -
randomization  
▪ Cotinine -confirmed [ADDRESS_338990] -randomization   
Trial go/no -go criteria for proceeding to a subsequent Phase II trial are: (1) satisfaction with ACT on Vapi[INVESTIGATOR_277607] 3.5 out of 5; and, (2) relative to control, evidence of better outcomes on at least 1 of 3 efficacy 
endpoints: change in readi ness to quit (mean difference in Contemplation Ladder change scores ≥ 1), 24 -hour 
quit attempts (≥ 5% difference), and cotinine -confirmed 30 -day point prevalence abstinence from all 
nicotine/tobacco products at 3 months (≥ 5% difference).  
 
Efficacy benchmarks were based on clinically meaningful differences in Contemplation Ladder (ie., at least one -
step change in average ladder score) or behavior change outcomes (5% difference in 24 -hour quit attempts, 30 -
day PPA rates).  
 
4.2 Study Population  
We will include n=60 participants in the pi[INVESTIGATOR_4251]. Participants will be YA e -cigarette users who are interested in 
using a digital intervention designed to motivate and support vapi[INVESTIGATOR_82608]. The 60 participants will be 
recruited over the course of approximately 1 month, based on previous trials which used a similar national 
recruitment strategy (e.g.,  targeted Facebook and social media  ads, UW Classified ads, Twitter  and Craigslist 
posts , and study flyers ).  
 
Inclusion of Women & Minorities  
We will actively seek participants who are diverse in their gender identity, including people who identify as 
cisgender men and women and those who identify transgender and gender expansive. We will also make every 
effort to ensure that members of diverse racial/ethnic groups are adequately represented in the study by 
[CONTACT_277682] (e.g. Craigslist ads in cities with a high proportion of 
racial/ethnic minority residents) and use of the Facebook advertising platfo rm to target on user interests and 
affiliations. In previous studies we have achieved at least 25% minority participation in trials using these 
methods. In the most recent large trial of a web -delivered intervention [28], the sample was 27% racial minority  
and 8% Hispanic/Latino. In our EQQUAL pi[INVESTIGATOR_799], 27% identified as racial/ethnic minority.  We will program 
the recruitment website to ensure that 25% identify as racial/ethnic minority.  
 
4.3 Study Design  
This is a pi[INVESTIGATOR_2268], randomized controlled trial (n=60  with 1:1 allocation to the two treatment arms ) to test the 
primary outcome of treatment acceptability  and efficacy for the ACT on Vapi[INVESTIGATOR_277608]. the control  program.  We will 
test the interventions using a 3 -mont h treatment period, and, consistent with the evaluation period in our 
previous cessation app pi[INVESTIGATOR_799], our primary outcomes will be assessed at the 3 -month end -of-treatment 
mark.  
RG1122763  
 
            Page 17 of 53   
  
4.3.1 Primary Objectives  
• Develop  the pi[INVESTIGATOR_4251] -ready version of the ACT on Vapi[INVESTIGATOR_277609] -related targets  
4.3.2 Primary Endpoint s 
• Treatment acceptability as indicated by o verall  treatment  satisfaction rating  
• Treatment efficacy:  
o Change in Contemplation Ladder  scores  from  baseline to [ADDRESS_338991] -randomization  
4.4 Estimated Accrual :  
 1 month  
 
4.5 Name [CONTACT_790]/Funding Source : National Institutes of Health  
 
5.[ADDRESS_338992] ELIGIBLITY  
 
5.1 Inclusion Criteria  
• age 18 -30 
• current weekly user of e -cigarette product(s) for the last 30 days  
• has a smartphone either  an Android (running version 10.1  or higher) or iPhone  (running iOS 
version 13 or higher)  
• experience downloading and using one or more apps on their smartphone  
• have a mobile  data plan and/or access to WiFi to support the use of  the ACT on Vapi[INVESTIGATOR_277603] 
• has access to text messaging  
• has an email address  
• US resident, with a US mailing address  
• willing to complete all study procedures  
• comfortable reading and writing in English  
 
5.2 Exclusion Criteria  
• currently using other tobacco cessation treatments  at the time of screening , including 
pharmacotherapy or behavioral support  (note : use of these treatment is allowable  during trial 
participation ) 
• member of the same household as another research participant  
• currently in prison  
• Google voice number  as sole phone number , due to its association with fraudulent study entry 
attempts  
• is ineligible per fraud prevention protocol  
• employees/family of investigator or study center  
 
 
6.[ADDRESS_338993] potential participants to a secure recruitment website, which provides basic 
information about the study and a portal to  the screening  survey.   
RG1122763  
 
            Page 18 of 53   
  
For participants who screen eligible on the recruitment website and provide their email address, we will 
instantly send them an email (and two reminders over a 7-day period) inviting them to provide informed 
consent and complete the baseline assessment.  
 
To prevent fraudulent study enrollment, we will use a multi -stage evaluation and exclusion of potential 
participants based on the following: IP address check for non -US addresses, proxy IP addresses, and IP addresses 
reported to have engaged in fraud; chec k for duplicate email addresses within -study; check for completing too 
many survey pages too fast, too many missing responses in the baseline survey (90% or more missing), 
inconsistent responses between screening and baseline; a final check for duplicate c ontact info provided based 
on name, phone number, or email address, or IP address; and a test SMS text message to check for virtual 
numbers.   
Research staff will contact [CONTACT_277683][INVESTIGATOR_50519] (e.g., very brief survey completion times or unusual patterns in email 
addresses). To further deter fraudulen t attempts to enter the study, no compensation will be provided for 
completion of the screening and baseline surveys.  
 
Participants completing this process will be enrolled in the study. This information will be stored in a secure 
research database behind FHCC firewall. See section 7.2 Enrollment Procedures and Appendix C for more 
details . 
 
7.0 TREATMENT PLAN  
 
7.1 Treatment Plan Overview  
 
Figure 2. Study Flow Chart  
 
 
 
 
 
 
 
 
 
 
7.2 Description of the interventions  
 
Control condition:  Incentivized text message check -ins. The control condition will be incentivized text message 
check -ins, similar to the design of Graham et al.’s [19] seminal study of a text messaging program (i.e., This is 
Quitting ) for vapi[INVESTIGATOR_82608]. Text message check -ins will occur at [ADDRESS_338994] -
randomization. At 2 weeks, participants will receive the following message: “Checking in: Have you cut down 
how much you vape nicotine in the past 2 weeks? Res pond w/ letter: A=I still use the same amount, B=I use less, 
C=I don’t use at  all anymore. Make sure to respond in the next 24 hrs to get your $5 incentive!” At 1 and 2 
months, they will receive the following message: “How’s it going? When was the last time you vaped nicotine, 
even a puff of someone else’s? Respond w/ letter: A - in the past 7 days, B - 8-30 days ago, C - More than 30 days 
ago. Make sure to respond in the next 24 hrs to get your $5 incentive!” Participants will be compensated $5 for 
each message that they respond to, for a maximum of $15 for responding to all 3 message s. In the Graham et al. 
[19] study, these text message check -ins were perceived as engaging and had placebo -like effects —e.g., 
participants assigned to the control condition, on average, expressed agreement with the following statements Informed Consent 
&  
Baseline 
Assessment  Access to ACT o n Vapi[INVESTIGATOR_277610]  + incentivized text 
messages  
3-month Follow -
up Assessment  Enrollment/  
Randomization  
Access to incentivized  
text messages   
RG1122763  
 
            Page 19 of 53   
 about these messages: “They helped me feel more confident about quitting,” “I liked being able to interact with 
the text messages,” and “They made me feel less alone in quitting.” Because their perceived value in support of 
quitting, use of the incentivize d text messages as a control condition allows for an estimate of the efficacy of the 
experimental ACT on Vapi[INVESTIGATOR_277586]. They are also designed to minimize attritio n among participants assigned to the 
control arm. All participants assigned to the control condition will be given access to the ACT on Vapi[INVESTIGATOR_277587].  Participant responses to text message check -ins will 
not be analyzed as a study outcome.  
 
Experimental condition: ACT on Vapi[INVESTIGATOR_007]:  The ACT on Vapi[INVESTIGATOR_277611] [ADDRESS_338995] -based [23, 24]. La ter sessions 
include prompts to reduce vapi[INVESTIGATOR_277589] a quit date for stoppi[INVESTIGATOR_17528] (non -therapeutic) nicotine and tobacco 
use. Text messages  will be used to (a) prompt completion of the next sess ion, and (b) push select intervention 
content to users. Only the n otifications will be tailored to the user’s level of quit readiness, with those who are 
not ready to quit in the next 30 days receiving values -focused, motivational messages and those who are ready 
to quit in the next 30 days receiving action -oriented mess ages (e.g., identifying and responding to triggers). 
Content of the six ACT on Vapi[INVESTIGATOR_277612]:  
 
Session [ADDRESS_338996] concept of creative hopelessness —
recognizing that efforts to control thoughts, feelings, or sensations related  to vapi[INVESTIGATOR_007] (e.g., urges to vape) can be 
counterproductive. Session 3 completes the topic of creative hopelessness and introduces cognitive defusion —
i.e., psychological distancing from thoughts —as an alternative to thought control as a strategy for copi[INVESTIGATOR_007] w ith 
triggers. Session 4 completes the topic of cognitive defusion, encourages setting a quit date in the next week, 
and prompts users to practice defusing from thoughts that they won’t be able to quit as part of quit planning. 
Session 5 starts with a refle ction on recent successes and difficulties, introduces the acceptance strategy of 
willingness as a means of handling triggers, and covers relapse prevention via self -compassion and re -
commitment to quitting. Session 6 also starts with a reflection on recen t successes and difficulties, reviews 
content from previous sessions, and ends with a video emphasizing the importance letting go of the need to 
control feelings, sensations, and thoughts in order to follow one’s valued life direction.   
 
New vapi[INVESTIGATOR_007] -targeted treatment content will include short animated videos embedded into the ACT - focused 
content that provide brief advice to quit and education about the risks of vapi[INVESTIGATOR_007], benefits of quitting, and 
evidence -based guidance on how to quit that  follows US Clinical Practice Guidelines for tobacco dependence 
treatment (e.g., information about cessation medications, setting a quit date, seeking support, etc.) [22]. In 
addition to this content, other areas in which the program will be targeted to ad dress vapi[INVESTIGATOR_277591] 
(1) the persona and narrative of the avatar guide, which will be presented as a former e -cigarette user who has 
successfully quit, (2) the narratives of other program users who share quit stories, (3) examples provided for 
implementing ACT strategies to reduce or quit vapi[INVESTIGATOR_007], and (4) the intervention content of the notifications that 
accompany the program. To address the issue of co -occurring alcohol and marijuana use and other tobacco use 
as impediments to quitting, ACT on Va pi[INVESTIGATOR_277592] (e.g., explaining how the ACT strategy of acceptance could also be applied to situations that trigger 
alcohol use or cigarette smoking) and personal narrative format (e .g., sharing stories of other YAs who quit 
vapi[INVESTIGATOR_277593], connecting personal values to decisions about substance use more 
broadly).  
 
RG1122763  
 
            Page [ADDRESS_338997] on Vapi[INVESTIGATOR_277594], at the same time intervals: [ADDRESS_338998] on Vapi[INVESTIGATOR_277613]  (e.g., 
Psychotherapy, Lifestyle 
Counseling)   Smartphone app + 
incentivized text message 
check -ins Smartphone app intervention plus incentivized check -
ins about changes in vapi[INVESTIGATOR_277614] (e.g., 
Psychotherapy, Lifestyle 
Counseling)   Incentivized text message 
check -ins   Incentivized check -ins assessing changes in vapi[INVESTIGATOR_277615]: Following the completion of the baseline  and the contact [CONTACT_277684] , the 
participant will receive a text message with a link. Once this link is clicked an automated algorithm will 
randomize participants 1:[ADDRESS_338999] on Vapi[INVESTIGATOR_277616], and the study team will send an 
email  and/or text message  indicating that they are enrolled in the study.  
 
If assigned to the ACT on Vapi[INVESTIGATOR_204494], the email will include login credentials to the app. If in [ADDRESS_339000] the opportunity to complete the follow -up survey either by [CONTACT_277685] .  
 
Baseline data : For participants who screen eligible on the recruitment website and provide their email address, 
we will instantly send them an email (and two reminders over a 7-day period) inviting them to complete a 
secured online survey to provide informed consent and complete the baseline assessment s (see Table 2 below) .  
At baseline, we will also collect email, phone number, and mailing address.  
 
3-month follow -up data:  The follow -up data collection protocol is as follows: Assessment Day -14: Mailed 
reminder of upcoming survey, with $2 pre -incentive included; Day 0: First email  and/or text  invitation with link 
to online survey; Day 5: Second email  and/or text  invitation with link to online survey; Day 9: Third email and/or 
text invitation with link to online survey; Days 10 to 18: Eight attempts to complete telephone version of survey 
(one call per day); Day 18: Send mailed version of survey. Participants w ill receive an incentive of $50 for the 
follow -up survey completed and an additional $25 for returning cotinine results if asked. In addition, an extra 
incentive of $[ADDRESS_339001] invitation and complete the survey 
online within 24 hours. Based on p revious trials using these same procedures [19, 28], we expect that 80% of 
participants will complete assessments via web -based survey, ~2% by [CONTACT_648], and ~3-4% by [CONTACT_277686] . 
7.4 The schedule of assessments  is provided  in Table 2 below.  Participant compensation  
Participants will receive up to $ 102 for participating in this study. Specifically,  participants will receive 
compensation based on the following structure:  
• $5 for responding to each of three text message assessments of e -cigarette use, for a total of up to $15  
• $2 in a pre -incentive letter for the 3 -month follow -up 
• $50 for the 3-month follow -up survey completed in any modality  
• $10 bonus for completing the 3 -month follow -survey within 24 hours of the initial email invitation  
RG1122763  
 
            Page 21 of 53   
 • $25 for returning cotinine results (if asked)  
 
8.[ADDRESS_339002] EVALUATION  
 
8.1 Data Collection Overview  
Table  2. Schedule  of assessments  
 
Measure   
# items  Screen ing 
Survey  
  
Baseline  
Survey  
  
3-mo. Follow -up  
Survey  
Primary Purpose  
Eligibility criteria  11 X   Eligibility  
Demographics  10  X  Sample description  
e-FTCD (severity of dependence)  6  X X Sample description  
Tobacco/nicotine use history  9  X  Sample description  
Contemplation Ladder (readiness 
to quit)  1  X X Primary outcome  
Recent tobacco/nicotine use  3  X X Primary outcome  
Saliva cotinine  n/a   X Primary outcome  
Outside tobacco treatment  2  X X Concomitant treatment  
Treatment satisfaction  8   X Primary outcome  
Treatment adherence (tracked 
automatically)  n/a   X Primary outcome  
Abstinence self -efficacy  1  X X Exploratory  
AIS cravings subscale 
(psychological flexibility)  9  X X Exploratory  
Valuing Questionnaire 
(psychological flexibility)  [ADDRESS_339003] 30 -day alcohol and cannabis 
use 2  X X Exploratory  
Agent Persona Instrument (avatar 
perceptions)  25   X Exploratory  
Adverse event s     X Safety monitoring  
Total number of items   11 62  73  
Estimated duration (mins)   5-10  30-35 35-40  
 
8.2 Enrollment Procedures  
 
The study recruitment website provides basic information about the study, FAQ, information about the study 
team and Fred Hutchinson Cancer Center (FHCC), and a portal to online screening survey.  
 
Individuals who do not meet eligibility criteria will be sent an email notifying them that they were not enrolled 
and provide both the link to Smokefree.gov and the 800 -QUIT -NOW phone number for cessation support.  
 
We will use the identical enrollment method proven successful in our previous, remotely -conducted RCTs. 
Specifically, for participants who screen eligible on the recruitment website and provide their email address, we 
will instantly send them an email (and  two reminders over a 7-day period) inviting them to provide informed 
consent and complete the baseline assessment.  
To address potential fraudulent responses to web -based screening surveys, we will use the same methods used 
in our previous studies: CAPTCHA verification, ineligibility if the IP address was previously used or suspi[INVESTIGATOR_15665], 
and telephone contact [CONTACT_277687][INVESTIGATOR_50519] 
(e.g., very brief survey completion times or unusual patterns in email addresses). To further deter fraudulent 
attempts to enter the study, no compensation will be provided for c ompletion of the brief (< 10 min) screening 
and baseline surveys.  
 
RG1122763  
 
            Page [ADDRESS_339004] manager (Edit Serfozo) with questions about the study (contact [CONTACT_277688]). The informed consent will be collected and stored in the secure database behind FHCC firewall  (see 
DSMP for additional details) . Participants who complete the enrollment process will receive a copy of the 
informed consent via email for future reference.  
 
Baseline Assessment . The baseline survey assesses demographics, tobacco/nicotine use history and current 
vapi[INVESTIGATOR_277617] , and  use of electronic cigarettes. More details below in section 9.3. The baseline survey data 
will be collected and stored in a research database behind FHCC firewall  (see DSMP for additional details) .  
 
Following the completion of the baseline survey and contact [CONTACT_277689] a text 
message. Once this link is clicked an email and /or a text message will be sent indicating that they are enrolled in 
the study.  
 
Participants will be randomized to either the ACT on Vapi[INVESTIGATOR_277618]. The randomization algorithm will use a permuted -block design with random block sizes, with stratification 
by [CONTACT_5019] (>5) vs. low (5 or less) readiness to quit on the Contemplation Ladder . 
 
If applicable, t he email and /or text message will provide participants  with a link to the login credentials  of the 
ACT on Vapi[INVESTIGATOR_277619] . If in 3 days the participant has not logged onto the app, they will receive a text message 
reminder. If in 3 more days the participant has still not logged onto the app, study staff will reach out by [CONTACT_277690].  
8.3 Assessments/On -Study Clinical Evaluations  
A complete schedule of assessments is provided in Table 2 above. Measures collected at baseline will also be 
collected at the 3 -month follow -up timepoint  except for  questions related to  demographics, severity of 
dependence and tobacco/nicotine use history , as answers to these questions will be used to describe our study 
population.   
 
All data from these assessments will be collected via web - based, telephone, or mailed surveys.   
8.3.[ADDRESS_339005] for Cigarette Dependence (e - FTCD) [57, 58] and the 1 -item Contemplation Ladder [56] will be 
used to assess e -cigarette dependence and readiness to quit using e -cigarettes, respectively. Nicotine and 
tobacco use history will be assessed using items derived from major epi[INVESTIGATOR_50123] s urveys (e.g., BRFSS, PATH).  
8.3.[ADDRESS_339006] on Vapi[INVESTIGATOR_277620] 3.5 falls between ratings of “somewhat satisfied” (3) and “mostly satisfied” (4).  
8.3.3 Efficacy for cessation  
 
Efficacy will be assessed via : (1) self-reported 24 -hour quit attempt, (2) change in readiness to quit, and (3) 
cotinine -confirmed 30 -day point prevalence abstinence.  
 
 
Self-reported 24 -hour quit attempt  
Making a 24-hour quit attempt between baseline and 3 -month follow -up will be assessed via self -report at the 
3-month follow -up. 
RG1122763  
 
            Page 23 of 53   
  
Change in readiness to quit  
The single -item Contemplation Ladder will be used to evaluate readiness to quit.  Change between baseline and 
3-month follow -up will be evaluated as in indicator of efficacy.  
 
Cotinine -confirmed 30 -day point prevalence abstinence from all nicotine and tobacco  
We will assess  30-day point prevalence abstinence (PPA) from all nicotine and tobacco use (excluding FDA -
approved pharmacotherapi[INVESTIGATOR_014]) at [ADDRESS_339007] -randomization, biochemically confirmed via saliva cotinine. For 
comparability with the only previous trial of a digital i ntervention for YA vapi[INVESTIGATOR_82608] (i.e., This is Quitting 
trial [19]), 30 -day PPA from vapi[INVESTIGATOR_277621]: (“In the past 30 days, did you vape 
at all, even a puff of someone else’s?”), and item instructions wi ll encourage participants to focus on all nicotine -
containing vapi[INVESTIGATOR_277622]. Items assessing 30 -day PPA from cigarette smoking and other 
tobacco use will be worded similarly. We will biochemically confirm self -reported abstinence from vapi[INVESTIGATOR_277623] - therapeutic nicotine and tobacco products at follow -up among those who report 30 -day PPA. Saliva 
cotinine tests (Alere iScreen) will be sent to participants via mail  and they will upload photos of the test results 
via a secure online s tudy portal.  
 
Participants who report using nicotine replacement therapy ( NRT) for tobacco cessation within 7 days of the 
scheduled date of cotinine testing will be considered abstinent without testing, since cotinine cannot distinguish 
e-cigarette and other tobacco use from NRT use and only method that can potentially make this dis tinction --
urinary analysis of minor tobacco alkaloids (e.g., anatabine/anabasine) [63] —isn’t feasible in a remote trial 
design with national recruitment.  
8.3.[ADDRESS_339008] of the 
interventions on alcohol and cannabis co -use (e.g, number of days of use in the past month) will be explored 
using web -based Timeline Followback [65] to assess alcohol and cannabis use over the 30 days prior to the 
assessment. Acce ptance of vapi[INVESTIGATOR_277624] e -cigarette version of the Avoidance and 
Inflexibility Scale (AIS), w ith a  subscale measuring acceptance of bodily  sensati ons (cravings ) [30]. The AIS 
subscale is highly correlated [25], so to limit respondent burden, we will administer only the [ADDRESS_339009] relationship with abstinence in previous work [25].  Values -
guided action will be assessed using the 10 -item Valuing Questionnaire [41], which has two subscales: Values 
Progress (5 items) and Values Obstruction (5 items). Change in abstinence self -efficacy will be assessed via a 
single -item rating of confid ence in one’s ability to quit vapi[INVESTIGATOR_007], measured at baseline and 3 months.   The Agent 
Persona Instrument (API) [42] will be administered as a treatment process measure only in the ACT on Vapi[INVESTIGATOR_277625]. This 25 -item  scale has four subscales: (1) credible, (2) 
facilitating learning, (3) engaging, and (4) human -like. This scale is most often used in studies of online learning 
to assess the effectiveness of a pedagogical agent.  
Adverse events will be collected by a web -based survey (on Day 21, 42, 63, and at the 3 -month follow -up time 
point).  
 
9.[ADDRESS_339010] DISCONTINUATION OF ACTIVE TREATMENT  
 
Participants can choose to discontinue their participation in this study at any time for any reason.  
 
10.0 CONCOMITANT MEDICATIONS  
 
Use of non -study cessation treatments will be assessed at the 3 -month follow -up. 
 
RG1122763  
 
            Page 24 of 53   
 11.0 ADVERSE EVENTS  
 
11.1 Adverse Events  
This is a low -risk study  testing the feasibility and preliminary efficacy of a behavioral intervention . Because this is 
a vapi[INVESTIGATOR_277626], some participants may quit using nicotine and may experience the physical and 
psychological consequences of  nicotine  abstinence, such as nicotine withdrawal symptoms. As part of the 
informed consent procedures, participants will be informed about potential nicotine withdrawal symptoms and 
effects of abstinence. The intervention provides strategies designed to cope more effectively with symptoms of 
nicotine withdrawal. Finally, participants will be given information on pharmacotherapy for tobacco  cessation 
(e.g., nicotine patch) and how to obtain these medications.  
11.[ADDRESS_339011] coordinator and outcome assessors will monitor participants’ progress and 
responses to surveys for adverse events and protocol compliance. The study coordinator will complete quarterly 
reports on participant progress and s tatus, any adverse events, and any protocol deviations.  
Reporting.  
All study staff working on the trial will be trained and required to report all unexpected and adverse events to 
the project coordinator and the Principal Investigator. A form will be available for this purpose. Adverse events 
beyond what would be expected  in the course of vapi[INVESTIGATOR_277627]’s IRB in 
accordance with Fred Hutch policy.  
 
Reporting SAEs . For AEs meeting the criteria for an SAE, regardless of attribution, the study coordinator 
will inform the Fred Hutch IRB per their reporting guidelines and will complete and submit a NIH SAE 
report form within 72 hours of the reported event. Should additio nal information become available after 
the initial report, a revised report will be submitted as soon as possible . 
Reporting AEs that do not meet the criteria for SAE. All reported AEs will be collected and reported via 
the study’s electronic database. AEs that are expected will be summarized at the time of continuation 
review.  
Reporting UEs that do not meet the criteria for AEs. The study team will report any UEs to the Fred 
Hutch IRB per their reporting guidelines.  Fred Hutch will report the UE to the sponsor in accordance 
with the protocol.  
Definitions  
In general, unexpected events (UEs) include any event, adverse or otherwise, that was not described as part of 
the study risks. For this trial, an example of an unexpected event that is not adverse is a participant who has 
become very unhappy with trial pr ocedures. Adverse events (AEs) are any untoward occurrence with a trial 
participant whether or not it can be considered to be related to their vapi[INVESTIGATOR_277626]. Examples of 
RG1122763  
 
            Page 25 of 53   
 adverse events in this trial could include development or worsening of depression symptoms. Serious adverse 
events (SAEs) include any AE that results in death, a real risk of dying, inpatient hospi[INVESTIGATOR_059], persistent or 
significant disability/incapacity , or AEs that require intervention to prevent permanent impairment or damage. 
In this trial, an example of a serious adverse event would be a suicide attempt.  
Management of SAEs or other study risks  
UEs, AEs, and SAEs will be reported to the Principal Investigator [INVESTIGATOR_277628]. If 
there is any doubt as to whether an event qualifies as a UE, AE, or SAE, staff members will be trained and 
encouraged to err on the side of cau tion – and to bring the event to the Principal Investigator’s attention for 
review. The PI [INVESTIGATOR_259534], AEs, and SAEs.  
Attribution  
The independent medical monitor  will decide if a UE should be classified as an AE. If an event is classified as an 
AE, further attribution will be determined, as follows:  
• Related – AEs that are definitely, probably, or possibly related to the intervention.  
• Not Related – AEs that are doubtfully related or clearly not related to the intervention.  
 
12.[ADDRESS_339012] quarterly reviews of study progress, including recruitment and retention, adverse events, and protocol 
adherence. A detailed DSMP in included in Appendix A.  
 
13.0 DATA MANAGEMENT/CONFIDENTIALITY  
 
The investigator will ensure that data collected conform to all established guidelines. Each participant  is 
assigned a unique number to protect participant  confidentiality. Only Fred Hutch IRB -approved project staff will 
have access to study data. All data will be maintained on a secure -access drive in permission -restricted folders 
only accessible to project staff. All workstations and servers are physically secured in locked offices, reside 
behind the Fred Hutch firewall, and fully participate in Windows N T security. The data study folder will be 
further safe -guarded against unauthorized access by [CONTACT_277691].  
In no case will pa rticipant  identifiers or data be provided to any person or entity outside the IRB -approved 
project team. Protected health information will not be disclosed, copi[INVESTIGATOR_530], transmitted by [CONTACT_6968], or transmitted in 
total or in part to anyone not connected with the approved protocol and not approved by [CONTACT_259568]. 
We will limit our acquisition of identifiable information to the minimum amount of information necessary to link 
participant  data, obtain contact [CONTACT_259569], and collect pertinent  data necessary to 
complete the study aims.   
Any data included in manuscripts or publications stemming from this study will be presented as aggregate data 
only, and in a way that no individual could be identified.  At the end of the study, after all manuscripts are 
published, all identifiable files a nd crosswalks will be destroyed in accordance with Fred Hutch IRB policy (7 
years after the end of the study). Electronic media used to store all data will be cleaned or destroyed so the data 
is not retrievable. As a result of these measures, we do not exp ect any invasion of privacy or breach of 
confidentiality.  
 
When any study personnel are no longer a part of the research team, the PI [INVESTIGATOR_259535]’s access to 
all study data and notify the Fred Hutch Information Security Officer of such action.  
 
Online Surveys . The study database will be designed and maintained by [CONTACT_259570], kept behind FHCC firewall. 
Only key study staff will have access to the study database system. All staff have received Human Subject 
RG1122763  
 
            Page [ADDRESS_339013] on Vapi[INVESTIGATOR_277629] s for 90 days . 
Text messages will be used to (a) prompt completion of the next session, and (b) push select  intervention  
content  to users. Notifications  will be tailored  to the user’s  level  of quit readiness, with  those who are not ready 
to quit in the next 30 days receiving values -focused, motivational messages and those who are ready to quit in 
the next 30 days receiving action -oriented messages (e.g., identifying and responding to triggers).   
All study participants will receive incentivized text message check -ins at [ADDRESS_339014] -
randomization.  
All communication with study participants will occur over Secure Sockets Layer (SSL) and no information or 
phone number will be shared by [CONTACT_277692].  
 
14.0 STATISTICAL CONSIDERATIONS  
 
14.1 Study Design  
Randomized controlled 2 -arm pi[INVESTIGATOR_4251]  
14.2 Primary/Secondary Endpoints/Hypotheses and Analytical Methods  
We will calculate descriptive statistics (e.g., means, proportions) for the ACT on Vapi[INVESTIGATOR_277630] (i.e., mean level of overall satisfaction with ACT on Vapi[INVESTIGATOR_007], with 3.5 on a 5 -point 
scale being the “go” criterion). For the three cessation related -outcomes, we will evaluate differences 
descriptively to determine whether ACT on Vapi[INVESTIGATOR_277631] 1 of 3 
efficacy endpoints as the final “go” criterion: change in readiness to quit (mean difference in Contemplation 
Ladder change scores ≥ 1), 24 -hour quit attempts (≥ 5% difference), and cotinine -confirmed 30 -day point 
prevalence abstinence from all nicotine/tobacco products at 3 months (≥ 5% difference). Given that pi[INVESTIGATOR_277632] [66, 
67], we will focus on descriptive differences as an alternative to hypothesis testing. Similarly, since a single effect 
size derived from a small sample is an inherently unreliable estimate of the true intervention effect size [67], we 
aimed to reduce the likelihood of early abandonment of a potentially promising treatment by [CONTACT_277693] a clinically meaningful effect on one of three cessation -relat ed outcomes as the “go” criterion for efficacy.  
14.3 Sample Size and Power  
We plan to accrue 60 participants in the pi[INVESTIGATOR_4251]. A sample size of 30 per arm is consistent with the NIDA Stage 
Model of behavioral treatment development, which suggests that pi[INVESTIGATOR_277633] 15 -30 
participants per arm for prel iminary evaluation of the intervention [36].  
14.[ADDRESS_339015] information survey the participant will receive a  text 
message with a link. Once this link is clicked an automated algorithm will randomize participants 1:[ADDRESS_339016] on Vapi[INVESTIGATOR_277634] -only control arm. The randomization algorithm will use a permuted -block 
RG1122763  
 
            Page 27 of 53   
 design with random block sizes, with stratification by [CONTACT_5019] (>5) vs. low (5 or less) readiness to quit on the 
Contemplation Ladder [56]. Only the unblinded study biostatistician will have access to treatment assignment. 
Although we project, based on our pr evious work [28], that the majority of outcome assessments will be 
completed via web -based survey, any outcome evaluator who has direct contact [CONTACT_277694] a cceptability of the ACT on 
Vapi[INVESTIGATOR_158664] . 
14.5 Missing Data  
Participants with missing tobacco use data will be considered non -abstinent [73] in the primary analysis. We will 
also report the results of sensitivity analyses using complete case analysis of those providing follow -up data. If 
there is a substantially differential rate of missing data (either self -report or cotinine analytic results) across 
arms, we will use complete case analysis in the primary outcome analysis instead of missing= tobacco use . 
14.6 Ethnic and Gender Distribution Chart  
Projected Target Accrual  
ETHNIC AND GENDER DISTRIBUTION CHART  
 
TARGETED / PLANNED ENROLLMENT: Number of Subjects  
Ethnic Category   
Sex / Gender  
 
Females  Males  Total  
Hispanic or Latino  3 2 5 
Not Hispanic or Latino  28 27 55 
Ethnic Category Total of All Subjects*  31 29 60 
 
Racial Categories  
  
American Indian / Alaska Native  1 1 2 
Asian  1 1 2 
Native Hawaiian or Other Pacific Islander  0 0 0 
Black or African American  2 1 3 
White  25 24 49 
More Than One Race  2 2 4 
Racial Categories: Total of All Subjects*  [ADDRESS_339017] -TRIAL [LOCATION_003]BILITY STUDY  
 
Objectives:  
Conduct  a diary study  with young adults (n =10) to assess user satisfaction with the app and its components as 
well as program utilization (n=10)  and additional modifications needed to continue with the ACT on Vapi[INVESTIGATOR_277635]3 phase of this study .  
 
16.1.1  Study Population   
We will recruit 10 YA e -cigarette users, ages 18 -30, who meet basic eligibility criteria for the trial described 
below .  
 
Participants will be recruited nationally via one or more recruitment strategies used successfully in our previous 
studies (e.g, social media, targeted Craigslist ads).  
16.1.[ADDRESS_339018] a diary study as a field -based evaluation of its 
usability. Usability is the extent to which a digital intervention can be easily navigated and understood by [CONTACT_277695] [52]. Usability is a critical outcome of the intervention development pro cess, as low usability can 
undermine engagement with the intervention as well as its potential efficacy for tobacco cessation [53].  
16.1.3  Primary Objective:  
Continued  development of the ACT on Vapi[INVESTIGATOR_277601]. The 
ACT on Vapi[INVESTIGATOR_277602].  
16.2 Estimated Accrual:  
We estimate that our recruitment efforts will lead to : 
• 120 screened, 40 eligible and 10 enrolled.  
We estimate recruitment to take 2 -3 weeks  
16.3 Eligibility:  
16.3.1  Inclusion Criteria  
• age 18 -30 
• current weekly user of e -cigarette product(s)  
• owns an Android phone or iPhone  
• has an email address  
• US resident, with a US mailing address  
• willing to complete all study procedures  
• comfortable reading and writing in English  
 
16.3.2  Exclusion Criteria  
• currently using other tobacco cessation treatments  at the time of screening , including 
pharmacotherapy or behavioral support   
• previous participation in a Fred Hutch vapi[INVESTIGATOR_277636]  
• currently in prison  
• member of the same household as another research participant  
• Google voice number as sole phone number, due to its association with fraudulent study 
entry attempts  
RG1122763  
 
            Page 29 of 53   
 16.4 Registration  
Potential participants will be recruited via social media (e.g. Facebook, Twitter ). Initial screening for participation 
will be conducted via web -based survey. Individuals deemed eligible will be contact[CONTACT_277696]; individuals remaining eligible and interested will be invited to attend  an 
online, video -based visit.  
16.[ADDRESS_339019] on Vapin g to their personal phone (Android or iPhone). Participants will be instructed to use 
the program for 6 days  and to keep a daily diary to report on their usage of and satisfaction with the program. 
Daily diaries will follow a semi -structured format, includ ing assessments of when they used the app, what 
prompted them to open it, what features they accessed, and what their overall experience was like. They will 
also be asked about any technical difficulties encountered and about ease of navigation. Following completion 
of the diary entries, they will be asked to attend a final debriefing session which will include a semi - structured 
exit interview to assess (a) usage and satisfaction with the app, and (b) the impact of ACT on Vapi[INVESTIGATOR_277637] e -
cigarette use.  
 
These procedures are consistent with best practices and usability testing of government -funded cessation 
programs [52] and have been successfully implemented previously in our treatment development work. After 
the diary study, the UX Researcher will work w ith the team of investigators to use data gleaned from the diary 
study to inform any needed changes to ACT on Vapi[INVESTIGATOR_007]’s content and structure as well as to address any 
technical difficulties experienced by [CONTACT_70513].  The software development team  will then make changes needed 
to improve the usability and/or content of the app in preparation for the UH3 phase of the  trial.  
16.6 Participant Compensation  
 
Diary study participants will be compensated up to $1 40 for completion all activities. Compensation will be pro -
rated and dispersed as follows:  
 
• $10 for the baseline visit . 
• $10 for mid-point check in . 
• $40 for the final debriefing visit . 
• $10 for each daily diary entry, up to $ 60 (for 6 days) .  
• $20 bonus for completing all 6 diary entries.   
 
16.7 Enrollment Procedures  
 
Participants will be recruited nationally through online services (e.g., Facebook, Twitter  advertisements). 
Recruitment materials will direct potential participants to a web -based screening survey. The survey provides Onboarding 
online video 
meeting &  
Verbal 
consent  Access to 
ACT o n 
Vapi[INVESTIGATOR_277638] -in 
call at 
midpoint of 
the daily diary 
entries  Daily Diary 
entry for 6 
days  Final exit 
interview   
RG1122763  
 
            Page 30 of 53   
 basic information about the study to allow individuals to choose whether or not to proceed, then assess basic 
eligibility criteria. Individuals who do not meet eligibility criteria will be provided with the following cessation 
resources via e -mail; the Smo kefree.gov and the 800 -QUIT -NOW phone number to reach their state’s quitline.  
 
 
Phone screening & informed consent : 
Study staff will call individuals who are deemed potentially eligible based on the initial online screening. During 
this call, the purpose and procedures of the study will be explained in further detail and key eligibility criteria 
will be re -assessed to e nsure consistency of answers. Those who remain eligible and interested will be invited 
and scheduled for the online onboarding meeting . Study staff will email the study information sheet to the 
individual to review before the  online meeting .  
 
Diary Study o nboarding video meeting . We will email participants the information needed to access the online 
meeting, which will be conducted and recorded via video conference. The onboarding meeting will be 
conducted by [CONTACT_277697] [ADDRESS_339020] on Vap ing app and will 
receive assistance with downloading the app. During this meeting, participants will also be asked about their 
motivation to quit vapi[INVESTIGATOR_007]. The brief (10 -15 minutes) mid -study session call and the final exit interview will also 
be scheduled. Aft er the onboarding meeting, study staff will email participants their log -in credentials for the 
ACT on Vapi[INVESTIGATOR_277639] -study feedback call and their final exit interview.  
 
16.8 Assessments/Evaluations  
 
Onboarding video call (Day 1):   Vapi[INVESTIGATOR_277640], motivation (importance and confidence) to change vapi[INVESTIGATOR_277641].  
 
Daily diary entry (Days 2 -7): Participants will be instructed to use ACT on Vapi[INVESTIGATOR_277642] 6 days  and to 
submit a daily diary to report on their usage of and satisfaction with the program. Daily diaries will 
follow a structured format, including assessments of when they used the app, what prompted them to 
open it, what features they accessed, and what  their overall experience was like. They will also be asked 
about the specific device and operating system they used to access the app, any technical difficulties 
encountered and about ease  of navigation.  
 
Mid-study check in call (Day 3-4): the UX Researcher will connect briefly with each participant for a 10 –
15-minute check in about their experience and engagement with the ACT on Vapi[INVESTIGATOR_277603]. Qualitative 
research notes will be taken during this call.  
 
Final exit interview (Day 8): Following completion of the diary study, participants will be asked to attend 
an online video meeting for a final debriefing session which will include a semi -structured exit interview 
to assess (a) usage and satisfaction with the app, and (b) the impact  of ACT on Vapi[INVESTIGATOR_277637] e -
cigarette use and engagement with the app. Participants will also be asked to report any technical 
difficulties they may have experienced.   
 
 
16.[ADDRESS_339021] on Vapi[INVESTIGATOR_277603]’ s content and 
structure as well as to address any technical difficulties experienced by [CONTACT_70513].  
 
The Moby [CONTACT_259555]. programming team will then make changes needed to improve the usability and/or content of 
the app  and will  complete additional modifications to the ACT on Vapi[INVESTIGATOR_277643] . The next  version of ACT on Vapi[INVESTIGATOR_277603], that will be developed after the diary study, will be used in the  
future ( UH3 ) phase of this study.  
 
17.0 REFERENCES  
 
1. Schulenberg JE, Johnston LD, O'Malley PM, Bachman JG, Miech  RA, Patrick ME, et al. Monitoring the 
Future National Survey Results on Drug Use, 1975 -2019. Volume II, College Students & Adults Ages 19 -60. 
Institute for Social Research; 2020.  
2. Cornelius ME, Wang TW, Jamal A, Loretan CG, Neff LJ. Tobacco Product Use Among Adults - United 
States, 2019. MMWR Morb Mortal Wkly Rep. 2020;69(46):1736 -42. Epub 2020/11/20. doi: 
10.[ZIP_CODE]/mmwr.mm6946a4. PubMed PMID: 33211681; PubMed Central PMCID: PMCPM C7676638  
3. Tackett AP, Hébert ET, Smith CE, Wallace SW, Barrington -Trimis JL, Norris JE, et al. Youth use of e - 
cigarettes: Does dependence vary by [CONTACT_169259]? Addict Behav. 2021;119:106918. Epub 2021/04/03. doi: 
10.1016/j.addbeh.2021.106918. PubMed PMID: 3379891 8; PubMed Central PMCID: PMCPMC8113136.  
4. Buu A, Hu YH, Wong SW, Lin HC. Comparing American college and noncollege young adults on e - 
cigarette use patterns including polysubstance use and reasons for using e -cigarettes. J Am Coll Health. 
2020;68(6):610 -6. Epub 2019/03/26. doi: 10.1080/07448481 .2019.1583662. PubMed PMID: 30908151.  
5. Doran N, Brikmanis K, Petersen A, Delucchi K, Al -Delaimy WK, Luczak S, et al. Does e -cigarette use 
predict cigarette escalation? A longitudinal study of young adult non -daily smokers. Prev Med. 2017;100:279 - 
84. Epub 2017/06/07. doi: 10.1016/j.ypmed.201 7.03.023. PubMed PMID: 28583658; PubMed Central PMCID: 
PMCPMC5481155.  
6. Wills TA, Knight R, Sargent JD, Gibbons FX, Pagano I, Williams RJ. Longitudinal study of e -cigarette use 
and onset of cigarette smoking among high school students in Hawaii. Tob Control. 2017;26(1):34 -9. Epub 
2016/01/27. doi: 10.1136/tobaccocontrol -2015 -052705. PubMed PMID: 26811353; PubMed Central PMCID: 
PMCPMC4959970.  
7. Gordon T, Karey E, Rebuli ME, Escobar Y, Jaspers I, Chi Chen L. E -Cigarette Toxicology. Annu Rev 
Pharmacol Toxicol. 2021. Epub 2021/09/24. doi: 10.1146/annurev -pharmtox -042921 -084202. PubMed PMID: 
34555289.  
8. US Department of Health and Human Services. E -cigarette Use Among Youth and Young Adults: A Report 
of the Surgeon General. U.S. Department of Health and Human Services, Centers for Disease Control and 
Prevention, National Center for Chronic Disease Prev ention and Health Promotion, Office on Smoking and 
Health, 2016.  
9. Pi[INVESTIGATOR_154321] K, Peto R, Reeves GK, Green J, Beral V. The 21st century hazards of smoking and benefits of 
stoppi[INVESTIGATOR_007]: a prospective study of one million women in the [LOCATION_006]. Lancet. 2013;381(9861):133 -41. Epub 
2012/10/31. doi: 10.1016/s0140 -6736(12)[ZIP_CODE] -6. PubMed PM ID: 23107252; PubMed Central PMCID: 
PMCPMC3547248.  
10. Villanti AC, McKay HS, Abrams DB, Holtgrave DR, Bowie JV. Smoking -cessation interventions for U.S. 
young adults: a systematic review. Am J Prev Med. 2010;39(6):564 -74. Epub 2010/11/19. doi: 
10.1016/j.amepre.2010.08.009. PubMed PMID: 21084078.  
11. Berg CJ, Krishnan N, Graham AL, Abroms LC. A synthesis of the literature to inform vapi[INVESTIGATOR_277644]. Addict Behav. 2021;119:106898. Epub 2021/04/25. doi: 
10.1016/j.addbeh.2021.106898. PubMed PMID: 33894483; PubMed Central  PMCID: PMCPMC8113079.  
12. Rosen RL, Steinberg ML. Interest in Quitting E -cigarettes Among Adults in the [LOCATION_002]. Nicotine & 
Tobacco Research. 2019;22(5):857 -8. doi: 10.1093/ntr/ntz062.  
RG1122763  
 
            Page 32 of 53   
 13. Lee SJ, Rees VW, Yossefy N, Emmons KM, Tan ASL. Youth and Young Adult Use of Pod -Based Electronic 
Cigarettes From 2015 to 2019: A Systematic Review. JAMA Pediatr. 2020;174(7):714 -20. Epub 2020/06/02. doi: 
10.1001/jamapediatrics.2020.0259. PubMed PMID: 32478809; PubMed Central PMCID: PMCPMC7863733.  
14. Curry SJ, Sporer AK, Pugach O, Campbell RT, Emery S. Use of tobacco cessation treatments among young 
adult smokers: 2005 National Health Interview Survey. Am J Public Health. 2007;97(8):1464 -9. Epub 2007/06/30. 
doi: 10.2105/ajph.2006.103788. PubMed PMI D: 17600243; PubMed Central PMCID: PMCPMC1931476.  
15. Budd J, Miller B, Manning E, Lampos V, Zhuang M, Edelstein M, et al. Digital technologies in the public -
health response to COVID -19. Nature Medicine. 2020;26:1 -10. doi: 10.1038/s41591 -020-[ADDRESS_339022] sheet2021.  
17. Anderson M, Perron A, Jiang J. 11% of Americans don't use the internet. Who are they? : Pew Research 
Center; 2018 [cited 2018 October 25]. Available from: http://www.pewresearch.org/fact - 
tank/2018/03/05/some -americans -dont -use-the-internet -who -are-they/. 
18. Berg CJ, Romm KF, Patterson B, Wysota C, Abroms LC. Appeal of novel cessation intervention 
approaches among young -adult users of traditional and alternative tobacco products. Tob Use 
Insights.2021;14:1179173x211041123. Epub 2021/10/19. doi: 10.1177/117 9173x211041123. PubMed PMID: 
34658625; PubMed Central PMCID: PMCPMC8516370.  
19. Graham AL, Amato MS, Cha S, Jacobs MA, Bottcher MM, Papandonatos GD. Effectiveness of a Vapi[INVESTIGATOR_277645] e -Cigarette Users: A Randomized Clinical Trial. JAMA 
Intern Med. 2021;181(7):923 -30. Epub 2021/05/18. doi: 1 0.1001/jamainternmed.2021.1793. PubMed PMID: 
33999133; PubMed Central PMCID: PMCPMC8129897  
20. Hayes SC, Strosahl KD, Wilson KG. Acceptance and Commitment Therapy: An experimental approach to 
behavior change. [LOCATION_001]: Guilford Press; 1999.  
21. Hayes SC, Strosahl  KD, Wilson KG. Acceptance and Commitment Therapy: The process and practice of 
mindful change. [LOCATION_001]: The Guilford Press; 2011.  
22. Fiore MC, Jaén CR, Baker TB, Bailey WC, Benowitz NL, Curry SJ, et al. Treating tobacco use and 
dependence: 2008 update. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human 
Services, Public Health Service; 2008.  
23. Hayes SC, Luoma JB, Bond FW, Masuda A, Lillis J. Acceptance and commitment therapy: model, 
processes and outcomes. Behaviour Research and Therapy. 2006;44(1):1 -25. Epub 2005/11/23. doi: 
10.1016/j.brat.2005.06.006. PubMed PMID: 16300724.  
24. Hayes SC. Acceptance and Commitment Therapy, Relational Frame Theory, and the Third Wave of 
Behavioral and Cognitive Therapi[INVESTIGATOR_014]. Behav Ther. 2004;35:639 -65. 
25. Bricker J, Wyszynski C, Comstock B, Heffner JL. Pi[INVESTIGATOR_277646] -based 
Acceptance and Commitment Therapy for Smoking Cessation. Nicotine Tob Res. 2013. Epub 2013/05/25. doi: 
10.1093/ntr/ntt056. PubMed PMID: 23703730.  
26. Bricker JB, Bush T, Zbikowski SM, Mercer LD, Heffner JL. Randomized Trial of Telephone -Delivered 
Acceptance and Commitment Therapy Versus Cognitive Behavioral Therapy for Smoking Cessation: A Pi[INVESTIGATOR_16116]. 
Nicotine Tob Res. 2014. Epub 2014/06/18. doi: 1 0.1093/ntr/ntu102. PubMed PMID: 24935757.  
27. Bricker JB, Mull KE, Kientz JA, Vilardaga R, Mercer LD, Akioka KJ, et al. Randomized, controlled pi[INVESTIGATOR_277647] a smartphone app for smoking cessation using acceptance and commitment therapy. Drug Alcohol Depend. 
2014. Epub 2014/08/03. doi: 10.1016/j.d rugalcdep.2014.07.006. PubMed PMID: 25085225.  
28. Bricker JB, Mull KE, McClure JB, Watson NL, Heffner JL. Improving quit rates of web -delivered 
interventions for smoking cessation: full -scale randomized trial of WebQuit.org versus Smokefree.gov. 
Addiction. 2018;113(5):914 -23. Epub 2017/12/14. doi: 10. 1111/add.[ZIP_CODE]. PubMed PMID: 29235186.  
29. Gifford EV, Kohlenberg B, Hayes SC, Pi[INVESTIGATOR_98803] H, Pi[INVESTIGATOR_29832] M, Antonuccio D, et al. Does acceptance and 
relationship focused behavior therapy contribute to bupropi[INVESTIGATOR_273644]? A randomized controlled trial of 
Functional Analytic Psychotherapy and Acceptanc e and Commitment Therapy for smoking cessation. Behav 
Ther. 2011. doi: 10.1016/j.beth.2011.03.002.  
30. Gifford EV, Kohlenberg BS, Hayes SC, Antonuccio DO, Pi[INVESTIGATOR_277648], Rasmussen -Hall ML, et al. 
Acceptance -based treatment for smoking cessation. Behav Ther. 2004;35:689 -705. doi: 10.1016/S0005 - 
7894(04)[ZIP_CODE] -7. 
RG1122763  
 
            Page 33 of 53   
 31. Hernandez -Lopez M, Luciano MC, Bricker JB, Roales -Nieto JG, Montesinos F. Acceptance and 
Commitment Therapy for smoking cessation: A preliminary study of its effectiveness in comparison with 
cognitive behavioral therapy. Psychol Addict Behav. 2009;23(4 ):723 -30. Epub 2009/12/23. doi: 
10.1037/a0017632. PubMed PMID: 20025380.  
32. Bricker JB, Watson NL, Heffner JL, Sullivan B, Mull K, Kwon D, et al. A Smartphone App Designed to Help 
Cancer Patients Stop Smoking: Results From a Pi[INVESTIGATOR_9415], Acceptability, and 
Effectiveness. JMIR Form Res. 2020;4(1):e1665 2. Epub 2020/01/18. doi: 10.2196/[ZIP_CODE]. PubMed PMID: 
31951215.  
33. Bricker JB, Watson NL, Mull KE, Sullivan BM, Heffner JL. Efficacy of Smartphone Applications for Smoking 
Cessation: A Randomized Clinical Trial. JAMA Intern Med. 2020. doi: 10.1001/jamainternmed.2020.4055.  
34. McClure JB, Bricker J, Mull K, Heffner JL. Comparative -Effectiveness of Group -Delivered Acceptance and 
Commitment Therapy vs. Cognitive Behavioral Therapy for Smoking Cessation: A Randomized Controlled Trial. 
Nicotine Tob Res. 2018. Epub 2018/12/28. do i: 10.1093/ntr/nty268. PubMed PMID: 30590810.  
35. Fogg B. A behavior model for persuasive design; 2009. 40 p.  
36. Rounsaville BJ, Carroll KM, Onken LS. A stage model of behavioral therapi[INVESTIGATOR_11482]: Getting started 
and moving on from stage I. Clinical Psychology: Science and Practice. 2001;8(2):133 -42. doi: 
10.1093/clipsy/8.2.133.  
37. Karekla M, Savvides SN, Gloster A. An Avatar -Led Intervention Promotes Smoking Cessation in Young 
Adults: A Pi[INVESTIGATOR_148757]. Ann Behav Med. 2020;54(10):747 -60. Epub 2020/05/10. doi: 
10.1093/abm/kaaa013. PubMed PMID: 32383736.  
38. Heffner JL, Watson NL, Serfozo E, Kelly MM, Reilly ED, Kim D, et al. Avatar -led digital program for sexual 
and gender minority young adult smoking cessation: Intervention development and results of a single - arm pi[INVESTIGATOR_2284]. JMIR Form Res. in press.  
39. Vogel EA, Ramo DE, Meacham MC, Prochaska JJ, Delucchi KL, Humfleet GL. The Put It Out Project (POP) 
Facebook Intervention for Young Sexual and Gender Minority Smokers: Outcomes of a Pi[INVESTIGATOR_2268], Randomized, 
Controlled Trial. Nicotine Tob Res. 2020;22(9):1614 -21. Epub 2019/09/29. doi: 10.1093/ntr/ntz184. PubMed 
PMID: 31562765; PubMed Central PMCID: PMCPMC7443590.  
40. Heffner JL, Mull KE, Watson NL, McClure JB, Bricker JB. Long -term smoking cessation outcomes for 
sexual minority vs. non -minority smokers in a large randomized, controlled trial of two web -based interventions. 
Nicotine Tob Res. 2019. Epub 2019/07/11. d oi: 10.1093/ntr/ntz112. PubMed PMID: 31290550.  
41. Smout M, Davies M, Burns N, Christie A. Development of the Valuing Questionnaire (VQ). Journal of 
Contextual Behavioral Science. 2014;3(3):164 -72. doi: https://doi.org/10.1016/j.jcbs.2014.06.001.  
42. Baylor A, Ryu J. The API (Agent Persona Instrument) for Assessing Pedagogical Agent Persona2003.  
43. Bricker JB, Copeland W, Mull KE, Zeng EY, Watson NL, Akioka KJ, et al. Single -arm trial of the second 
version of an acceptance & commitment therapy smartphone application for smoking cessation. Drug Alcohol 
Depend. 2017;170:37 -42. Epub 2016/11/22. doi:  10.1016/j.drugalcdep.2016.10.029. PubMed PMID: 27870987; 
PubMed Central PMCID: PMCPMC5183543.  
44. Heffner JL, Watson NL, Serfozo E, Mull KE, MacPherson L, Gasser M, et al. A Behavioral Activation 
Mobile Health App for Smokers With Depression: Development and Pi[INVESTIGATOR_277649] a Single -Arm Trial. JMIR 
Form Res. 2019;3(4):e13728. Epub 2019/11/28. d oi: 10.2196/[ZIP_CODE]. PubMed PMID: 31774405; PubMed Central 
PMCID: PMCPMC6913543.  
45. Heffner JL, Kelly MM, Waxmonsky J, Mattocks K, Serfozo E, Bricker JB, et al. Pi[INVESTIGATOR_277650] -Delivered Acceptance and Commitment Therapy Versus Smokefree.gov for Smokers With Bipolar 
Disorder. Nicotine Tob Res. 2019. Epub 2019/ 12/29. doi: 10.1093/ntr/ntz242. PubMed PMID: 31883336.  
46. Berg CJ. Internet -based interventions for smoking cessation show inconsistent effects across trials, with 
only some trials showing a benefit. Evidence -based Nursing. 2011;14(2):47 -8. Epub 2011/03/23. doi: 
10.1136/ebn.14.2.47. PubMed PMID: 21421974.  
47. Civljak M, Sheikh A, Stead LF, Car J. Internet -based interventions for smoking cessation. Cochrane 
Database Syst Rev. 2010(9):CD007078. Epub 2010/09/09. doi: 10.1002/14651858.CD007078.pub3. PubMed 
PMID: 20824856.  
RG1122763  
 
            Page 34 of 53   
 48. Graham AL, Cobb NK, Papandonatos GD, Moreno JL, Kang H, Tinkelman DG, et al. A randomized trial of 
Internet and telephone treatment for smoking cessation. Archives of Internal Medicine. 2011;171(1):46 -53. 
Epub 2011/01/12. doi: 10.1001/archinternmed.201 0.451. PubMed PMID: 21220660.  
49. Hutton HE, Wilson LM, Apelberg BJ, Tang EA, Odelola O, Bass EB, et al. A systematic review of 
randomized controlled trials: Web -based interventions for smoking cessation among adolescents, college 
students, and adults. Nicotine Tob Res. 2011;13(4):227 -38. Epub 2011/02/26. doi: 10.1093/ntr/ntq252. PubMed 
PMID: 21350042.  
50. Shahab L, McEwen A. Online support for smoking cessation: a systematic review of the literature. 
Addiction. 2009;104(11):1792 -804. Epub 2009/10/17. doi: 10.1111/j.1360 -0443.2009.[ZIP_CODE].x. PubMed PMID: 
19832783.  
51. Webb TL. Commentary on Shahab & McEwen (2009): Understanding and preventing attrition in online 
smoking cessation interventions: a self -regulatory perspective. Addiction. 2009;104(11):1805 -6. Epub 
2009/10/17. doi: 10.1111/j.1360 -0443.2009.[ZIP_CODE].x. PubM ed PMID: 19832784.  
52. Stoddard JL, Augustson EM, Mabry PL. The importance of usability testing in the development of an 
internet -based smoking cessation treatment resource. Nicotine Tob Res. 2006;Dec;[ADDRESS_339023] 1:S87 -93. PMID: 
17491175.  
53. Cheh JA, Ribisl KM, Wildemuth BM. An assessment of the quality and usability of smoking cessation 
information on the Internet. Health Promot Pract. 2003;4:278 -87. 
54. Brooke J. SUS: A "quick and dirty" usability scale". In: Jordan PW, Thomas B, Weerdmeester BA, 
McClelland AL, editors. Usability Evaluation in Industry. London: Taylor and Francis; 1996.  
55. Pi[INVESTIGATOR_46746], Bullen C, Krishnan -Sarin S, Rigotti NA, Steinberg ML, Streck JM, et al. Defining and Measuring 
Abstinence in Clinical Trials of Smoking Cessation Interventions: An Updated Review. Nicotine Tob Res. 
2020;22(7):1098 -106. Epub 2019/07/05. doi: 1 0.1093/ntr/ntz110. PubMed PMID: 31271211.  
56. Biener L, Abrams DB. The Contemplation Ladder: validation of a measure of readiness to consider 
smoking cessation. Health Psychol. 1991;10(5):360 -5. Epub 1991/01/01. PubMed PMID: 1935872.  
57. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: 
a revision of the Fagerström Tolerance Questionnaire. British Journal of Addiction. 1991;86(9):1119 -27. 
58. Pi[INVESTIGATOR_46746], Baker TB, Benowitz NL, Smith SS, Jorenby [CONTACT_34479]. E -cigarette Dependence Measures in Dual Users: 
Reliability and Relations With Dependence Criteria and E -cigarette Cessation. Nicotine Tob Res. 2020;22(5):756 -
63. Epub 2019/03/16. doi: 10.1093/ntr/n tz040. PubMed PMID: 30874804; PubMed Central PMCID: 
PMCPMC7368344.  
59. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al. Varenicline, an alpha4beta2 
nicotinic acetylcholine receptor partial agonist, vs sustained -release bupropi[INVESTIGATOR_184207]: a randomized controlled trial. JAMA . 2006;296(1):47 -55. Epub 2006/07/06. doi: 
10.1001/jama.296.1.47. PubMed PMID: 16820546.  
60. Jorenby [CONTACT_34479], Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al. Efficacy of varenicline, an 
alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained -release bupropi[INVESTIGATOR_184208]: a randomized controlle d trial. JAMA. 2006;296(1):56 -63. Epub 2006/07/06. doi: 
10.1001/jama.296.1.56. PubMed PMID: 16820547.  
61. West R. The clinical significance of "small" effects of smoking cessation treatments. Addiction. 
2007;102(4):506 -9. Epub 2007/03/17. doi: 10.1111/j.1360 -0443.2007.[ZIP_CODE].x. PubMed PMID: 17362283.  
62. SRNT Subcommittee on Biochemical Verification. Biochemical verification of tobacco use and cessation. 
Nicotine & Tobacco Research. 2002;4(2):149 -59. Epub 2002/05/25. doi: 10.1080/14622200210123581. PubMed 
PMID: 12028847.  
63. Benowitz NL, Bernert JT, Foulds J, Hecht SS, Jacob P, Jarvis MJ, et al. Biochemical Verification of Tobacco 
Use and Abstinence: 2019 Update. Nicotine Tob Res. 2019. Epub 2019/10/02. doi: 10.1093/ntr/ntz132. PubMed 
PMID: 31570931.  
64. Hoeppner BB, Kelly JF, Urbanoski KA, Slaymaker V. Comparative utility of a single -item versus multiple -
item measure of self -efficacy in predicting relapse among young adults. Journal of substance abuse treatment. 
2011;41(3):305 -12. Epub 06/22. doi: 10. 1016/j.jsat.2011.04.005. PubMed PMID: 21700411.  
RG1122763  
 
            Page 35 of 53   
 65. Sobell LC, Brown J, Leo GI, Sobell MB. The reliability of the Alcohol Timeline Followback when 
administered by [CONTACT_20261]. Drug Alcohol Depend. 1996;42(1):49 -54. Epub 1996/09/01. 
PubMed PMID: 8889403.  
66. Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT 2010 statement: 
extension to randomised pi[INVESTIGATOR_228373]. Pi[INVESTIGATOR_277651]. 2016;2:64 -. doi: 
10.1186/s40814 -016-0105 -8. PubMed PMID: 27965879.  
67. Leon AC, Davis LL, Kraemer HC. The role and interpretation of pi[INVESTIGATOR_36156]. J 
Psychiatr Res. 2011;45(5):626 -9. Epub 2010/11/03. doi: 10.1016/j.jpsychires.2010.10.008. PubMed PMID: 
21035130; PubMed Central PMCID: PMCPMC3081994.  
68. MacKinnon DP, Lockwood CM, Hoffman JM, West SG, Sheets V. A comparison of methods to test 
mediation and other intervening variable effects. Psychol Methods. 2002;7(1):83 -104. Epub 2002/04/04. 
PubMed PMID: 11928892.  
69. MacKinnon DP. Introduction to Statistical Mediation Analysis. [LOCATION_001]: Erlbaum; 2008.  
70. Preacher KJ, Hayes AF. Asymptotic and resampling strategies for assessing and comparing indirect 
effects in multiple mediator models. Behav Res Methods. 2008;40(3):879 -91. Epub 2008/08/14. PubMed PMID: 
18697684.  
71. Fritz MS, Mackinnon DP. Required sample size to detect the mediated effect. Psychol Sci. 
2007;18(3):233 -9. Epub 2007/04/21. doi: PSCI1882 [pii] 10.1111/j.1467 -9280.2007.[ZIP_CODE].x. PubMed PMID: 
17444920.  
72. Cohen J. Statistical power analysis for the behavioral sciences. 2nd Edition. Hillsdale, NJ: Erlbaum; 1988.  
73. West R, Hajek P, Stead L, Stapleton J. Outcome criteria in smoking cessation trials: proposal for a 
common standard. Addiction. 2005;100(3):299 -303. Epub 2005/03/01. doi: ADD995 [pii] 10.1111/j.1360 - 
0443.2004.[ZIP_CODE].x. PubMed PMID: 15733243.  
74. Bricker JB, Wyszynski CM. Contextual cognitive behavioral therapi[INVESTIGATOR_277652]: Motivational 
interviewing and acceptance and commitment therapy. In: Hayes SC, Levin M, editors. Mindfulness and 
acceptance for addictive behaviors: Applying conte xtual CBT to substance abuse and behavioral addictions. 
Oakland, CA: New Harbinger; in press.  
  
RG1122763  
 
            Page 36 of 53   
 18.0 APPENDICES  
 
Appendix A:  DSMP  
  
  
 
0000 [enter Fred Hutch/UW Cancer Consortium  protocol number]  
 
            Page 37 of 53   
 Appendix A  
Data & Safety Monitoring Plan  
Version 2, 10/24/22  
 
1 UG3 DA057032 -01 
 
 
 
“ACT on Vapi[INVESTIGATOR_007]: Digital Therapeutic for Young Adult Vapi[INVESTIGATOR_277560]”  
 
PI: [INVESTIGATOR_259519], Jaimee L.  
Medical Monitor:  Panagis Galiatsatos, MD  
0000 [enter Fred Hutch/UW Cancer Consortium  protocol number]  
 
            Page 38 of 53   
 19.0 Table of Contents  
1 Summary of the protocol  39 
1.1 Brief description of the protocol  39 
1.2 The primary aims are:  39 
1.3 Primary outcome measures  39 
1.4 Inclusion/exclusion criteria  [ADDRESS_339024] to ensure the validity and integrity of the data  43 
4.2 Procedures to guarantee the accuracy and completeness of the data  43 
4.3 Procedures during data transmission  44 
4.4 Procedures during data analysis  44 
5 Regulatory issues  44 
5.1 Reporting mechanisms of AEs/SAEs to the IRB and NIDA  [ADDRESS_339025]  45 
6 Trial safety  45 
6.1 Potential risks of intervention and mitigation plan  45 
6.2 Risks related to research procedures and mitigation plan  45 
6.3 Benefits for participants  46 
7 Collection and reporting of AEs and SAEs  46 
7.1 Monitoring  46 
7.2 Reporting  47 
7.3 Definitions  47 
7.4 Management of SAEs or other study risks  47 
0000 [enter Fred Hutch/UW Cancer Consortium  protocol number]  
 
            Page 39 of 53   
 7.5 Attribution  47 
8 Trial efficacy  47 
8.1 Plans for interim analysis of efficacy data  47 
8.2 DSM plan administration  47 
1 Summary of the protocol  
1.1 Brief description of the protocol  
 
This study will adapt a digital Acceptance and Commitment Therapy (ACT) program into an app -based 
digital therapeutic for young adult ( YA) vapi[INVESTIGATOR_277653] a n incentivized text message control condition.  
1.2 The primary aims are:  
 
Aim 1  (Y1-Y2). Develop the ACT on Vapi[INVESTIGATOR_277654] -related targets.  
1.a. Gather input from users and subject matter experts (YAs who vape, team members with expertise 
in YA vapi[INVESTIGATOR_007]) to develop vapi[INVESTIGATOR_007] -focused content for the novel program.  
1.b. Complete Q -submission to obtain FDA feedback on the regulatory pathway for the intervention.  
1.c. Conduct a pi[INVESTIGATOR_4265] (n=60) to evaluate acceptability and preliminary efficacy of ACT on Vapi[INVESTIGATOR_277655].  
 
Aim 1 outcomes will be evaluated using the following go/no -go criteria to determine whether proceeding 
to a larger UH 3-phase study is warranted : (a) Completed FDA Q -submission. ( b) From the pi[INVESTIGATOR_4251], 
evidence that ACT on Vapi[INVESTIGATOR_277656] (overall satisfaction averaging at least 3.5 out of 5) and 
produces better outcomes than the control intervention on at least 1 of 3 efficacy endpoints: change in 
readiness to quit (mean dif ference in Contemplation Ladder change scores ≥ 1), 24 -hour quit attempts (≥ 
5% difference), and cotinine -confirmed 30 -day point prevalence abstinence from all nicotine/tobacco 
products at 3 months (≥ 5% difference).  
 
1.[ADDRESS_339026]-randomization  Biochemically  confirmed  30-
day abstinence  from all 
nicotine and tobacco 
products at follow -up 
(excluding FDA-approved 
pharmacotherapi[INVESTIGATOR_014])  
0000 [enter Fred Hutch/UW Cancer Consortium  protocol number]  
 
            Page 40 of 53   
 1.4 Inclusion/exclusion criteria  
 
Inclusion Criteria  
 
• age 18 -30 
• current weekly user of e -cigarette product(s) for the last 30 days  
• has a smartphone either an Android (running version 10.1 or higher) or iPhone (running iOS 
version 13 or higher)  
• experience downloading and using one or more apps on their smartphone  
• have a mobile data plan and/or access to WiFi to support the use of the ACT on Vapi[INVESTIGATOR_277657]  
• has access to text messaging  
• has an email address  
• US resident, with a US mailing address  
• willing to complete all study procedures  
• comfortable reading and writing in English  
Exclusion Criteria  
 
• currently using other tobacco cessation treatments at the time of screening, including 
pharmacotherapy or behavioral support (note: use of these treatment is allowable during trial 
participation)  
• member of the same household as another research participant  
• currently in prison  
• Google voice number as sole phone number, due to its association with fraudulent study entry 
attempts  
• is ineligible per fraud prevention protocol  
• employees/family of investigator or study center  
 
1.5 Power calculation and sample size  
 
Sample size determination . We plan to accrue 60 participants in the pi[INVESTIGATOR_4251]. A sample size of 30 per 
arm is consistent with the NIDA Stage Model of behavioral treatment development, which suggests that 
pi[INVESTIGATOR_277633] 15 -30 participants per arm for preliminary evaluation of the 
intervention [1].  
1.6 Schedule of assessments  
 
Measure   
# items  Screen ing 
Survey  
  
Baseline  
Survey  
  
3-mo. Follow -
up  Survey  
Primary Purpose  
Eligibility criteria  11 X   Eligibility  
Demographics  10  X  Sample description  
e-FTCD (severity of 
dependence)  6  X X Sample description  
Tobacco/nicotine use history  9  X  Sample description  
Contemplation Ladder 
(readiness to quit)  1  X X Primary outcome  
Recent tobacco/nicotine use  3  X X Primary outcome  
Saliva cotinine  n/a   X Primary outcome  
Outside tobacco treatment  2  X X Concomitant 
treatment  
Treatment satisfaction  8   X Primary outcome  
Treatment adherence (tracked 
automatically)  n/a   X Primary outcome  
0000 [enter Fred Hutch/UW Cancer Consortium  protocol number]  
 
            Page 41 of 53   
 Abstinence self -efficacy  1  X X Exploratory  
AIS cravings subscale 
(psychological flexibility)  9  X X Exploratory  
Valuing Questionnaire 
(psychological flexibility)  [ADDRESS_339027] 30 -day alcohol and 
cannabis use  2  X X Exploratory  
Agent Persona Instrument 
(avatar perceptions)  25   X Exploratory  
Adverse events  1   X Safety monitoring  
Total number of items   11 62  73  
Estimated duration (mins)   5-[ADDRESS_339028]  
 
Based on previous trials that used a similar national recruitment strategy  (ranging from 78 -862 
randomized/month) , we estimate enrollment of at least 120 participants /month, requiring a recruitment 
period of  less than  1 month for the UG3 phase (n=60) . 
2.3 Target population distribution  
 
We will actively seek participants who are diverse in their gender identity, including people who identify as 
cisgender men and women and those who identify transgender and gender expansive. We will also make 
every effort to ensure that members of diverse racial/ethnic groups are adequately represented in the 
study by [CONTACT_277682] (e.g. Craigslist ads in cities with a high 
proportion of racial/ethnic minority residents) and use of the Facebook advertising platfo rm to target on 
user interests and affiliations. In previous studies we have achieved at least 25% minority participation in 
trials using these methods. In the most recent large trial of a web -delivered intervention [ 7], the sample 
was 27% racial minority and 8% Hispanic/Latino. In our EQQUAL pi[INVESTIGATOR_799], 27% identified as 
racial/ethnic minority. Although the UG3 trial is not designed to ensure statistical power to evaluate effect 
moderators, we will program the recruit ment website to ensure that at least 2 5% identify as racial/ethnic 
minority.  
3 Data management and analysis  
3.1 Data acquisition and transmission  
 
Recruitment . Participants will be recruited nationally via recruitment strategies used successfully in 
previous studies conducted by [CONTACT_27156]: targeted Facebook ads; Craigslist ads in cities with a high 
prevalence of nicotine and tobacco use or racial/ethnic minority residence; other free methods of 
advertising on the Internet (e.g., Reddit, Twitter); ResearchMatch.org; and earned media generated by 
[CONTACT_259552]. Recruitment materials will direct potential participants to 
a recruitment website, which provides basic information about the study and a portal to  screening survey. 
In order to ensure that at least 25% of the sample identifies as racial/ethnic minority, we will program the 
website to limit recruitment of those who identify as non -Hispanic White to 75% and continue recruitment 
until the racial/ethnic minority recruitment goal of at least 25% is reached. This similar to recruitment 
cappi[INVESTIGATOR_277658].  
0000 [enter Fred Hutch/UW Cancer Consortium  protocol number]  
 
            Page [ADDRESS_339029] potential participants to a secure 
recruitment website, which provides basic information about the study and a portal to the screening  
survey. For participants who screen eligible on the recruitment website and provide their email address, 
we will instantly send them an email and/or text message (and two reminders over a 7-day period) inviting 
them to provide informed consent and complete the baseline assessment. Those not consenting and 
complet ing or not eligible w ill be sent an email notifying them that they were not enrolled and providing 
both the link to Smokefree.gov and the [ADDRESS_339030] 
results.  
 
Assessment instruments.  Structured assessment instruments will be administered by [CONTACT_169993] -based forms 
or by [CONTACT_277698]: (1) evaluate study eligibility and establish baseline characteristics 
of the sample, (2) evaluate study outcomes.  
 
App utilization data.  At randomization, participant s assigned to the ACT on Vapi[INVESTIGATOR_277659] a 
unique log -in ID to access their assigned app, which will serve as the link to the rest of their study data.  
 
Saliva cotinine testing.  Cotinine test kits will be shipped at each follow -up to all self -reported abstainers 
who have not used nicotine replacement therapy in the prior [ADDRESS_339031] email, phone number, and 
mailing address. The data collection protocol is as follows: Assessment Day -14: Mailed reminder of 
upcoming survey, with $2 pre -incentive included; Da y 0: First email  and/or  invitation with link to online 
survey; Day 5: Second email and/or text invitation with link to online survey; Day 9: Third email and/or text 
invitation with link to online survey; Days 10 to 18: Eight attempts to complete telephone version of survey 
(one call per day); Day 18: Send mailed version of survey; Participants will receive an incentive of  $50 the 
follow -up survey completed and an additional $25 for returning cotinine results if asked. In addition, an 
extra incentive of $[ADDRESS_339032] email  and/or text  invitation 
and complete the survey online within 24 hours. Based on previous trials using these same procedures 
[19, 28], we expect that 80% of participants will complete assessments via web -based survey, ~2% by 
[CONTACT_648], ~3 -4% by [CONTACT_277686].  
3.3 Data entry methods  
 
All screening, baseline, and outcome survey data will be entered either directly by [CONTACT_259581] (for participants who complete the surveys by [CONTACT_87068]) 
into a study database managed by [CONTACT_259570], LLC.  
 
3.[ADDRESS_339033] access to their assigned app protected with a login. All connections will be 
made using the secure sockets layer (SSL).  
0000 [enter Fred Hutch/UW Cancer Consortium  protocol number]  
 
            Page 43 of 53   
  
Participant data are maintained on a server in a locked server room at Fred Hutch. Full access to the 
server is restricted to two staff members of the Fred Hutch Public Health Sciences Information 
Technology (PHS -IT) group and the two developers of the stu dy management system.  
 
3.5 Data analysis plan  
 
To address Sex as a Biological Variable, we will explore whether outcomes described below are 
associated with sex assigned at birth. If they are, that variable will be added to the relevant models. 
Primary analyses will be conducted as described below : 
 To evaluate the go/no -go criteria for the pi[INVESTIGATOR_4251], we will calculate descriptive statistics (e.g., 
means, proportions) for the ACT on Vapi[INVESTIGATOR_277660] (i.e., mean 
level of overall satisfaction with ACT on Vapi[INVESTIGATOR_007],  with 3.5 on a 5 -point scale being the “go” criterion). For 
the three cessation related -outcomes, we will evaluate differences descriptively to determine whether 
ACT on Vapi[INVESTIGATOR_277631] 1 of 3 efficacy endpoints as the final “go” 
criterion: change in readiness to quit (mean difference in Contemplation Ladder change scores ≥ 1), 24 -
hour quit attempts (≥ 5% difference), and cotinine -confirmed 30 -day point prevalence abstinence from all 
nicotine/tobacco products at 3 months  (≥ 5% difference). Given that pi[INVESTIGATOR_277661] [ 5, 6], we will focus on 
descriptive differences as an alternative to hypothesis testing. Similarly, sinc e a single effect size derived 
from a small sample is an inherently unreliable estimate of the true intervention effect size [ 6], we aimed 
to reduce the likelihood of early abandonment of a potentially promising treatment by [CONTACT_277693] a clinically meaningful effect on one of three cessation -related outcomes as the “go” criterion for 
efficacy.  
 
Missing data . Participants with missing nicotine  use data will be considered non -abstinent [ 6] in the 
primary analysis. We will also report the results of sensitivity analyses using complete case analysis of 
those providing follow -up data. If there is a substantially differential rate of missing data (either self -report 
or cotinine analytic result s) across arms, we will use complete case analysis in the primary outcome 
analysis instead of missing= vapi[INVESTIGATOR_007]/ smoking.  
[ADDRESS_339034] to ensure the validity and integrity of the data  
To prevent fraudulent study enrollment, we will use a multi -stage evaluation and exclusion of potential 
participants based on the following: IP address check for non -US addresses, proxy IP addresses, and IP 
addresses reported to have engaged in fraud; chec k for duplicate email addresses within -study; check for 
completing too many survey pages too fast, completion of hidden responses (indicative of a bot), 
inconsistent responses between screening and baseline; a final check for duplicate contact [CONTACT_277699] d 
based on name, phone number, or email address, or IP address; and a test SMS text message to check 
for virtual numbers.  
4.2 Procedures to guarantee the accuracy and completeness of the data  
Data accuracy has two aspects in this trial: (1) accuracy of self -reported data by [CONTACT_259583], and (2) 
accuracy of data management. The trial has procedures for both, which will be reviewed annually by [CONTACT_277700].  
 
The ACT on Vapi[INVESTIGATOR_277662], and utilization data will be recorded for 
all participants  assigned to that arm . Study IDs in the database will be unrelated to any identifying 
information. Data will be checked for inconsistencies, omissions, and errors.  
 
Outcome assessors will receive training in data management and confidentiality procedures and will be 
responsible for data entry and management.  
0000 [enter Fred Hutch/UW Cancer Consortium  protocol number]  
 
            Page 44 of 53   
 4.3 Procedures during data transmission  
Forms used by [CONTACT_277701] -based forms. Data are maintained on a server in a 
locked server room at Fred Hutch. Full access to the server is restricted to two staff members of the Fred 
Hutch Public Health Sciences Information Technolog y (PHS -IT) group and the two developers of the 
study management system.  
 
Project staff access the study database from their computers via the Study Management (SM) Web site. 
The SM Web site is only accessible from specific Internet Protocol (IP) addresses used by [CONTACT_464]. All 
communication with the SM Web site occurs over S ecure Sockets Layer (SSL).  
4.[ADDRESS_339035] quality checks. 
Data quality will be assessed through a number of analytic methods. The study statistician will tabulate 
categorical variables with frequency counts , and for continuous variables we will examine descriptive 
statistics (mean, standard deviation, median, interquartile range, minimum, maximum), distributional 
characteristics (skewness, kurtosis, frequency histograms, normal probability plots), and associ ations 
(correlations, scatter plots).  Any free text or numeric values will be checked for range consistency, and 
outlying values.  
5 Regulatory issues  
5.1 Reporting mechanisms of AEs/SAEs to the IRB and NIDA  
 
Reporting SAEs  
It will be the responsibility of the PI [INVESTIGATOR_277663], 
reported to NIDA within [ADDRESS_339036] of AEs will be maintained and reported via the study’s electronic 
database. AEs that are expected will be summarized  quarterly for the study’s Medical Monitor and 
annually  at the  time of continuation review.  
 
Reporting UEs that do not meet the criteria for AEs  
The study team will report any UEs to the Fred Hutch IRB per their reporting guidelines.  Fred Hutch will 
report the UE to the sponsor in accordance with the protocol.  
5.[ADDRESS_339037] changes or amendments to the 
protocol. When approved, the modification will serve as the official report of the changes or amendment. 
Major changes to the protocol will be pre -approved b y the NIDA Program Officer.  
0000 [enter Fred Hutch/UW Cancer Consortium  protocol number]  
 
            Page [ADDRESS_339038] for the Medical 
Monitor to evaluate the safety of the trial and its continued progress.  
Complying with trial suspension reporting requirements  
Were the IRB or Clinical Trials Office to issue a temporary or permanent suspension of the trial, the trial’s 
Principal Investigators will immediately contact [CONTACT_20767]’s Program Offic er, Jana Drgonova, PhD  , National 
Institute on Drug Abuse, Clinical/Medical Branch , Bethesda, Maryland [ZIP_CODE] -9551. Phone: 301-827-
5933, Email:  [EMAIL_5400] .  
5.[ADDRESS_339039].  
6 Trial safety  
6.1 Potential risks of intervention and mitigation plan  
 
Therapeutic risks.  Therapeutic risks include the physical and psychological consequences of nicotine 
and tobacco abstinence, such as nicotine withdrawal symptoms. Participants will be informed of the 
discomfort associated with nicotine withdrawal, including common withdrawa l symptoms. Specifically, 
participants will be informed that, “ If you quit vapi[INVESTIGATOR_277664] , you may 
experience some short -term discomfort associated with nicotine withdrawal including irritability, 
depressed mood,  restlessness, difficulty sleepi[INVESTIGATOR_007], headaches, difficulty concentrating, and cravings to 
smoke. These symptoms typi[INVESTIGATOR_31228] a few weeks and then go away. ” Strategies for mitigating 
withdrawal -related risks will be provided (e.g., using over -the-counter medications for headaches, 
physical activity to help with mood and sleep, etc.).   Participants will also be informed of the possibility 
that the interventions provided as part of the study may not be effective in helpi[INVESTIGATOR_277665].  
 
Possibility that the study intervention may not help  the participant to quit using nicotine and tobacco  
products . Participants will receive information about the availability of pharmacotherapy to facilitate 
cessation, including nicotine replacement, bupropi[INVESTIGATOR_2394], or varenicline. They will also be informed of 
alternative behavioral support options such as counseling/su pport through their state quitline (1 -800-
QUIT -NOW).  
 
Assignment to incentivized text message control arm.  Potential study participants will be informed as 
part of the consent process that they have a [ADDRESS_339040] on Vapi[INVESTIGATOR_277666] y.  
 
6.2 Risks related to research procedures and mitigation plan  
Participants will be informed of the following research -related risks: (1) the possibility that answering 
some questions may be emotionally upsetting, and (2) the possibility of breach of confidentiality .  It is 
possible that some of the questions asked of participants may cause some emotional discomfort. There is 
also a small risk of breach of confidentiality if participant data, either in electronic or hard copy form, were 
to be accessed by [CONTACT_277702] . 
 
Emotional upset . On the study assessments, participants will be reminded that they have the choice to 
not answer any question that makes them uncomfortable.  
 
0000 [enter Fred Hutch/UW Cancer Consortium  protocol number]  
 
            Page [ADDRESS_339041] access to their 
assigned app protected with a login. All connections to web -based data collection forms will be made  
using the secure sockets layer (SSL).  
 
A Certificate of Confidentiality from the National Institutes of Health is in place to protect participants in 
this study from involuntary disclosure of information collected as part of the study. Participants will be 
informed both verbally and in writing that the Certificate of Confidentiality does not supersede federal 
and/or state laws governing exceptions to confidentiality (e.g., danger to self or others, mandated 
reporting of child or elder abuse/neglect). Similarly, participants will be notified that  agents of the Fred 
Hutchinson Cancer Center, the National Institutes of Health, and the FDA will be allowed to inspect 
sections of their study records, if requested. Otherwise, no information will be released to any individual 
or organization without thei r prior written authorization. Participants will be informed that the data from the 
study may be published; however, they will not be identified by [CONTACT_2300]. Participants will be informed that 
their identity will remain confidential unless law requires such di sclosure.  
 
All study personnel will receive required training in protection of human subjects in research as well as 
Good Clinical Practice training. Participants will be informed of therapeutic and research related risks as 
well as the safeguards and/or precautions taken to reduce these risks. The following procedures will be 
implemented to protect against the risks outlined above.  
 
Informed consent.   At the outset of the study, participants will be provided with detailed information 
about the study and provided with the opportunity to ask questions about study participation. Informed 
consent will be obtained following the guidelines of the Fred Hutch  Institutional Review Board. 
Participants will be reminded that they are free to withdraw from the study at any point.  
6.3 Benefits for participants  
Participants will be provided with information regarding potential benefits of participation in the study, 
including  the following intervention -related benefits : 1) the possibility that study participation  might help 
them to quit using nicotine and tobacco, and 2) access to a smartphone app to learn about their interest 
in quitting vapi[INVESTIGATOR_277596].  
 
Benefits of research procedures  
Participation in the trial’s surveys will not offer any direct benefits but will advance knowledge in many 
important areas of young adult vapi[INVESTIGATOR_82608]. Participants may have a positive feeling about 
participating in this effort by [CONTACT_277703]’s surveys.  
 
Other information  
Token monetary incentives are offered for completion of the study assessments. Although not the 
purpose of these token incentives, they may be perceived by [CONTACT_277704] a benefit to 
participation.  
[ADDRESS_339042] manager and outcome assessors will monitor participants’ progress and 
responses to surveys for adverse events and for protocol compliance . Participants will be asked to report 
changes in their physical and mental health, especially if treatment was required. An email will be sent to 
participants asking about changes in their health on Day 21, [ADDRESS_339043] 
the participant by [CONTACT_277705], if needed. Emergency and crisis resources will 
be provided to all study participants in the study consent, and at each adverse event collection time point.  
0000 [enter Fred Hutch/UW Cancer Consortium  protocol number]  
 
            Page 47 of 53   
 Adverse event assessment (“Have you experienced any changes in your health or well -being since you 
started the study?”)  will also be completed at the [ADDRESS_339044] manager  and the Principal Investigator. A form will be available for this purpose. The PI [INVESTIGATOR_277667]’s independent medical monitor for evaluation of its causal relationship with 
study intervention. (See Section 5 for a description of procedures for reporting AEs and SAEs to the IRB 
and to NIDA).  
7.3 Definitions  
In general, unexpected events (UEs) include any event, adverse or otherwise, that was not described as 
part of the study risks. An adverse event (AE) is any unexpected medical or psychiatric occurrence in a 
patient or clinical investigation participant adm inistered an intervention, which does not necessarily have 
a causal relationship with the treatment. This includes any clinical or laboratory change that does not 
commonly occur in that participant and is considered clinically significant.  
 
FDA 21CFR312.32 defines a serious adverse event (SAE) as any adverse experience that results in any 
of the following outcomes: death; a life -threatening adverse drug experience; inpatient hospi[INVESTIGATOR_8448]; a persi stent or significant disability/incapacity; or a congenital 
anomaly/birth defect. Important medical events that may not result in death, be life -threatening, or require 
hospi[INVESTIGATOR_277668], based on appropriat e judgment, 
they may jeopardize the patient or participant and may require medical or surgical intervention to prevent 
one of the outcomes in this definition. The judgment of whether a particular AE meets the above criteria 
for an SAE shall be determined by [CONTACT_1758]’s independent medical monitor . 
7.4 Management of SAEs or other study risks  
UEs, AEs, and SAEs will be reported to the Principal Investigator [INVESTIGATOR_259533]. If there is any doubt as to whether an event qualifies as a UE, AE, or SAE, staff members will be 
trained and encouraged to err on the side of caution – and to bring the event to the Principal 
Investigator’s attention for review. The PI [INVESTIGATOR_259534], AEs, and SAEs.  
Withdrawal from the study as a result of an AE or of therapeutic measures taken to treat an AE shall be at 
the discretion of the PI.  
7.5 Attribution  
The medical monitor will decide if a UE should be classified as an AE. If an event is classified as an AE, 
further attribution will be determined, as follows:  
 
Related – AEs that are definitely, probably, or possibly related to the intervention.  
Not Related – AEs that are doubtfully related or clearly not related to the intervention.  
8 Trial efficacy  
8.1 Plans for interim analysis of efficacy data  
As this is a pi[INVESTIGATOR_799], no interim efficacy analyses will be conducted.  
 
8.2 DSM plan administration  
Responsibility for data and safety monitoring  
0000 [enter Fred Hutch/UW Cancer Consortium  protocol number]  
 
            Page [ADDRESS_339045]. Heffner will oversee that data and safety monitoring plan for the trial , including consultation with the 
independent medical monitor who will make the final determination as to whether UEs, AEs, and SAEs 
are related to study interventions.  
 
Frequency of DSM reviews  
Data will be reviewed in the course of the trial on a quarterly basis. A full DSM report will be generated 
annually.  
 
Content of DSM report  
The content of the annual DSM report will follow this structure: (1) Brief description of the trial, (2) 
Baseline sociodemographic characteristics, (3) Retention and disposition of study participants, (4) Q.A. 
issues, (5) Regulatory issues, (6) AEs, (7) SA Es, (8) Efficacy. A copy of this report will be provided to the 
NIDA pro gram  officer annually.  
 
DSM Board Plan  
A DSMB is not needed for this low -risk, single -site trial of two behavioral interventions for smoking 
cessation.  
0000 [enter Fred Hutch/UW Cancer Consortium  protocol number]  
 
            Page 49 of 53   
 References  
 
1. Rounsaville BJ, Carroll KM, Onken LS. A stage model of behavioral therapi[INVESTIGATOR_11482]: Getting 
started and moving on from stage I. Clinical Psychology: Science and Practice. 2001;8(2):133 -42. doi: 
10.1093/clipsy/8.2.133.  
2. Vogel EA, Ramo DE, Meacham MC, Prochaska JJ, Delucchi KL, Humfleet GL. The Put It Out 
Project (POP) Facebook Intervention for Young Sexual and Gender Minority Smokers: Outcomes of a 
Pi[INVESTIGATOR_2268], Randomized, Controlled Trial. Nicotine Tob Res. 2020;22(9):1614 -21. Epub 2019/09/29. doi:  
3. Bricker JB, Mull KE, McClure JB, Watson NL, Heffner JL. Improving quit rates of web -delivered 
interventions for smoking cessation: full -scale randomized trial of WebQuit.org versus Smokefree.gov. 
Addiction. 2018;113(5):914 -23. Epub 2017/12/14. doi: 10.1 111/add.[ZIP_CODE]. PubMed PMID: 29235186.  
4. Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT 2010 
statement: extension to randomised pi[INVESTIGATOR_228373]. Pi[INVESTIGATOR_277651]. 2016;2:64 -. 
doi: 10.1186/s40814 -016-0105 -8. PubMed PMID: 27965879.  
5. Leon AC, Davis LL, Kraemer HC. The role and interpretation of pi[INVESTIGATOR_36156]. J 
Psychiatr Res. 2011;45(5):626 -9. Epub 2010/11/03. doi: 10.1016/j.jpsychires.2010.10.008. PubMed 
PMID: 21035130; PubMed Central PMCID: PMCPMC3081994.  
6. West R, Hajek P, Stead L, Stapleton J. Outcome criteria in smoking cessation trials: proposal for 
a common standard. Addiction. 2005;100(3):299 -303. Epub 2005/03/01. doi: ADD995 [pii] 
10.1111/j.1360 - 0443.2004.[ZIP_CODE].x. PubMed PMID: 15733243.  
7. Tackett AP, Hébert ET, Smith CE, Wallace SW, Barrington -Trimis  JL, Norris JE, et al. Youth use 
of e- cigarettes: Does dependence vary by [CONTACT_169259]? Addict Behav. 2021;119:106918. Epub 
2021/04/03. doi: 10.1016/j.addbeh.2021.106918. PubMed PMID: 33798918; PubMed Central PMCID: 
PMCPMC8113136.  
 
 
 
  
0000 [enter Fred Hutch/UW Cancer Consortium  protocol number]  
 
            Page [ADDRESS_339046] on Vapi[INVESTIGATOR_158664]  
 
  
 
 
  

0000 [enter Fred Hutch/UW Cancer Consortium  protocol number]  
 
            Page [ADDRESS_339047] on Vapi[INVESTIGATOR_277561]: Recruitment  
 

0000 [enter Fred Hutch/UW Cancer Consortium  protocol number]  
 
            Page 52 of 53   
  

0000 [enter Fred Hutch/UW Cancer Consortium  protocol number]  
 
            Page 53 of 53   
  
